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REGULATION OF APOPTOSIS BY XIAP UBIQUITIN-LIGASE 
ACTIVITY 
 
Andrew James Schile, Ph.D. 
The Rockefeller University 2009 
 
Virtually all animal cells have the known ability to self-destruct by 
undergoing apoptosis, a morphologically distinct form of programmed cell 
death.  The proper regulation of apoptosis is critical for both development 
and tissue homeostasis, and inhibition of apoptosis contributes to the 
development and progression of cancer.  Inhibitor of Apoptosis Proteins 
(IAPs) can bind to and inhibit caspases, the key executioners of apoptosis.  
Because IAPs are frequently over-expressed in human tumors, they have 
become major pharmacological targets for developing new cancer 
therapeutics.  Many IAPs contain RING domains that function as E3 
ubiquitin-ligases to regulate the abundance of IAPs themselves and their 
binding partners by engaging the ubiquitin system.  The precise 
physiological function of individual mammalian IAPs and their role as E3-
ubiquitin ligases in situ remain largely obscure.  
Here, we investigated the function of XIAP ubiquitin-ligase activity 
by deleting the RING motif via gene targeting in the mouse.  Mice 
expressing XIAP ΔRING were fertile, born in expected proportions, and 
 
were not obviously prone to disease in a pathogen-free environment.  
Removing the RING finger motif stabilized XIAP protein in apoptotic 
thymocytes, demonstrating that XIAP ubiquitin-ligase activity is a major 
determinant of XIAP protein stability.  However, consistent with earlier 
reports on XIAP-null mice, we found no detectable abnormalities in 
apoptosis of mutant thymocytes.  On the other hand, ΔRING embryonic stem 
cells and fibroblasts had elevated caspase-3 enzyme activity and impaired 
ubiquitination of active caspase-3 during apoptosis.  Furthermore, XIAP 
ΔRING embryonic fibroblasts were strongly sensitized to TNF-α-induced 
apoptosis.  Similar results were obtained with XIAP-null mice.  Finally, 
deletion of the RING also improved the survival of mice in the Eµ-Myc 
lymphoma model.  The improved prognosis corresponded to increased 
apoptosis and decreased abundance of proliferating B-cells in the bone 
marrow, and a curtailed incidence of leukemia.  This demonstrates a 
physiological requirement of XIAP E3 ubiquitin-ligase activity for the 
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1.1 Introductory comment 
 
Cell death is a fundamental aspect of life in multicellular animals.  
Genetically encoded cell death pathways appear to function as early as the 
eight-cell blastocyst stage (Hardy et al., 1989), and continue during 
embryonic development to mold the shape and function of organs.  Cell 
death functions throughout adult life as a cellular quality control mechanism 
by removing superfluous or harmful cells.  Cell death can be considered a 
critical counterpoint to proliferation.  Indeed, the two phenomena are linked 
in some situations: excessive proliferation can provoke cell death (Evan et 
al., 1992), while dying cells can signal their replacement by transmitting 
mitogenic signals (Ryoo et al., 2004).  
Virtually all animal cells have the ability to self-destruct by 
undergoing apoptosis, a morphologically distinct form of programmed cell 
death.  The conservation and diversification of apoptosis during the 
evolution of multicellular animals point to its involvement in many vital 
processes.  An understanding of how cells die is important for controlling 
pathologically misregulated cell death pathways.  For example, it is very 
likely that all tumor cells subvert cell death checkpoints in the process of 
becoming malignant (Hanahan and Weinberg, 2000).  Diseases as diverse as 
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stroke, neurodegeneration, and HIV infection are characterized by excessive 
cell death with a strong apoptotic component as well (Thompson, 1995). 
1.2 Historical perspective on programmed cell death  
 
 Nineteenth century biologists described cell deaths in developing 
embryos by noting cells with atypical appearances, mostly during 
metamorphosis (Clarke and Clarke, 1996).  The physiological nature of cell 
death was noted as early as 1842, when the German naturalist Karl Vogt 
described the disappearance of the notochord during toad metamorphosis.  A 
relationship between death and proliferation was later described in the rat 
retina (Tansley et al., 1937).  Rita Levi-Montalcini and colleagues noted that 
extraneous neurons are culled by cell death during development (Hamburger 
and Levi-Montalcini, 1949), and that survival factors can determine which 
cells live and die (Cohen and Levi-Montalcini, 1957; Levi-Montalcini and 
Hamburger, 1951).  Indeed, it was apparent by mid-century that death plays 
important roles in animal development (Glucksmann, 1951; Saunders, 
1966).    Richard Lockshin coined the phrase “programmed cell death” to 
describe an active death process during metamorphosis in the tobacco worm 
Manduca (Lockshin and Williams, 1965).  This observation is very 
perceptive because it notes that death appears as a programmed fate.  Studies 
on the regressing tadpole tail helped to generalize these findings and 
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emphasize the role of macromolecular synthesis in developmental cell death 
(Tata, 1966).   
Apoptosis was the first form of programmed cell death to be defined 
by a distinct morphology common to diverse cell types during death (Kerr et 
al., 1972).  Apoptosis was coined from a Greek word describing a “shedding 
off” of leaves to refer to a stereotyped pattern of changes that include 
membrane blebbing, nuclear condensation, cytoplasmic compaction and 
DNA fragmentation (Kerr et al., 1972; Wyllie et al., 1980).  The original 
paper offers a wealth of prescient insights.  For instance, the authors note 
that recurring apoptosis reflects a conserved physiological program in 
normal and diseased tissues.  Apoptosis functions in the “focal elimination 
of cells during normal embryonic development”, and “seems to be involved 
in cell turnover in many healthy adult tissues”.  Furthermore, they speculate 
that apoptosis may function in “therapeutically induced tumor regression” 
and “hyperplasia might sometimes result from decreased apoptosis rather 
than increased mitosis.”  Their ultrastructural analyses of apoptosis in 
different contexts also highlight phagocytosis, as all apoptotic cells appeared 
engulfed by other cells in situ.  They also postulate that apoptosis is distinct 
from necrotic cell death, which occurs after insults provoke cell rupture and 
inflammation (Wyllie et al., 1980). 
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Early studies on the death of developing T-cells in the thymus 
implicated an intracellular nuclease in the orderly DNA fragmentation that 
occurs during apoptosis (Wyllie, 1980), but the biochemical underpinnings 
of apoptosis remained elusive long after the term was coined.  Indeed, the 
importance of cell death remained somewhat understated until the discovery 
that BCL-2, a gene cloned at a chromosomal breakpoint in follicular 
lymphoma, can prolong the survival of cells deprived of cytokines and 
synergize with the proliferative oncogene c-Myc to immortalize B-cells 
(McDonnell et al., 1989; Vaux et al., 1988).  Transgenic mouse models of 
cancer reveal that coexpressed BCL-2 and c-Myc provoke high-grade 
lymphoma (McDonnell and Korsmeyer, 1991; Strasser et al., 1990).  These 
novel discoveries showed that a factor involved in cell death could serve as 
an oncogene, and awakened interest in the field.   
The molecular basis for apoptosis was uncovered in large part through 
genetic studies in the nematode worm Caenorhabditis elegans.  C. elegans is 
well suited to the study of programmed cell death because each animal 
generates cells during development that die invariantly (Sulston and Horvitz, 
1977).  Genetic screens identified ced-3 (cell death abnormal) and ced-4 as 
genes required specifically for programmed cell death during development 
(Ellis and Horvitz, 1986).  Another gene, ced-9, was identified with an 
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opposing pro-survival function: gain-of-function mutations prevent cell 
death, while loss of ced-9 function kills cells that normally live (Hengartner 
et al., 1992).  Some cell death genes have functions conserved throughout 
the evolution of multicellular animals; ced-9 is homologous to human BCL-
2, and BCL-2 expression rescues loss of ced-9 function (Hengartner and 
Horvitz, 1994; Vaux et al., 1992).   
1.3 Caspases 
 
The key insight into the mechanism of apoptotic cell death was the 
observation that ced-3 encodes a cysteine protease similar to a mammalian 
protease, ICE (interleukin-1-beta converting enzyme-1) (Xue et al., 1996; 
Yuan et al., 1993).  CED-3 and ICE (now caspase-1) are the founding 
members of the caspase family of proteases, which are so named because 
they harbor an active site containing a cysteine residue, and preferentially 
cleave their substrates after aspartate residues, although glutamate is also 
tolerated (Nicholson, 1999).  There are least ten caspases in the human and 
mouse genomes, and many of them function in apoptosis (Thornberry and 
Lazebnik, 1998).  Caspases are expressed as weakly active precursors that 
require allosteric activation or proteolysis by other caspases before they can 
cleave their substrates efficiently.   
A typical caspase precursor contains an amino-terminal prodomain, a 
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large subunit, and a small subunit.  Proteolysis between the domains releases 
the prodomain and allows the large and small subunits to dimerize; this unit 
proceeds to dimerize to form an active tetramer (Nicholson, 1999).  All 
caspases described to date have a dimerization interface that appears to be 
critical for activity (Shi, 2002b).  Caspases recognize a tetrapeptide 
sequence, P4-P3-P2-P1, and cleave after the carboxyl-terminal residue (P1).  
P1 is usually Asp (though sometimes Glu), while P3 is preferentially Glu for 
mammalian caspases.  Different caspases have distinct but often overlapping 
preferences for the P4-P3-P2-P1 sequence. 
The mammalian caspases involved in apoptosis can be grouped into 
two broad categories based on their domain structures.  Caspases with large 
prodomains (e.g., caspases-8 and -9) generally function as initiator caspases, 
and depend on allosteric activation and/or association with other factors for 
their activity (Shi, 2002b).  Caspases with shorter prodomains (e.g., 
caspases-3, -6. -7) appear to require cleavage, often by initiator caspases, to 
become active.  The large prodomains in initiator caspases contain additional 
domains used for associating with activating complexes through homotypic 
interactions.  Examples are the CARD (caspase recruitment domain) in 
caspase-9 and its allosteric activator, Apaf-1; and DED (death effector 
domain) in caspase-8 and its activator, FADD (Fas-associated death 
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domain). 
Caspases are only weakly active in their proenzyme forms, and 
effector caspases appear to require intrachain cleavage to function.  A 
framework for thinking about effector caspase activation comes from 
comparisons between the structures of inactive procaspase-7 and its active 
form (Chai et al., 2001b).  The overall structures of inactive and active 
caspase-7 are similar and both are dimers, but the peptide loops that 
comprise the active site adopt a different conformation in the active caspase.  
Cleavage between the small and large subunits of caspase-7 frees one of the 
active site loops from a restrained covalent linkage, and allows it to adopt a 
conformation that is conducive to forming an active site.  This mechanism 
applies to other initiator caspases, presumably (Shi, 2002b). 
Activated caspases can cleave a broad range of proteins during 
apoptosis; however, it is largely unclear which substrates must be cleaved 
for apoptosis to proceed.  The functional consequences of caspase cleavage 
are known for some substrates.  Nuclear lamin, for example, is cleaved by 
caspases to facilitate degradation of the nucleus during apoptosis (Takahashi 
et al., 1996).  The fragmentation of genomic DNA that can occur during 
apoptosis arises when ICAD, the inhibitor of the caspase-activated DNase 
CAD, is cleaved and inactivated (Liu et al., 1997; Sakahira et al., 1998).  
 8 
Membrane blebbing and nuclear disintegration arise when caspases cleave 
and activate ROCK1, a regulator of actin dynamics (Coleman et al., 2001; 
Croft et al., 2005).  Cleavage of β-catenin by caspases helps to promote 
detachment from cellular substrata, which may aid in clearance of apoptotic 
cells (Brancolini et al., 1997).  Since more than 400 human caspase 
substrates have been identified to date (Luthi and Martin, 2007), it is likely 
that a wide range of proteolyzed substrates contribute to apoptosis. 
Some caspases have functions that appear unrelated to apoptosis.  
Caspase-1, the founding member of the caspase family, processes a 
precursor of the interleukin-1 cytokine involved in immunity; caspase-1 
knockout mice are impaired in mounting a response to endotoxic shock (Li 
et al., 1995).  Caspase-8-null mice have abnormalities in heart development 
that are not easily explained by defective apoptosis (Varfolomeev et al., 
1998).  A secondary role for caspases in lymphocyte development is 
revealed by T-cells lacking caspase-8: mutant mice are immunodeficient, 
and lymphocytes from young mice have proliferative defects (Salmena and 
Hakem, 2005).  Furthermore, there are many documented cases where 
caspase activity does not lead to the death of a cell.  An apoptosis-like 
process occurs during spermatid development in Drosophila, where caspase 
activity is locally restricted to eliminate bulk cytoplasm without causing 
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death (Arama et al., 2003).  The differentiation pathway for macrophages 
(Sordet et al., 2002) and lens development in the eye (Ishizaki et al., 1998) 
require caspase activity as well. 
1.4 Activation of caspases 
 
There are two known routes to caspase activation in mammalian cells.  
The mitochondrial pathway (also known as the intrinsic pathway) is 
activated in response to diverse death stimuli that include genotoxic damage, 
oncogene activation, and developmental cues.  This route to apoptosis is so-
named because the activation steps appear to be controlled by factors 
localized in or near mitochondria.  An alternate pathway is activated through 
death receptors and figures prominently in immunity.  Some cell types 
require engagement of both pathways for efficient apoptosis. 
1.4.1 Activation through mitochondrial factors 
 
In addition to the ced-3 caspase, ced-4 is another gene required for 
programmed cell death of somatic cells in C. elegans (Ellis and Horvitz, 
1986).  Epistasis experiments place ced-4 upstream of ced-3 as its activator 
during apoptosis (Shaham and Horvitz, 1996a; Shaham and Horvitz, 1996b).  
Insight into CED-4 function came after its mammalian counterpart, Apaf-1 
(apoptotic protease related factor-1), was identified biochemically as an 
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activator of caspase-9 which promotes caspase-3 cleavage and activation in 
vitro (Li et al., 1997; Zou et al., 1997).  Activation of caspase-9 by Apaf-1 
requires ATP/dATP plus an additional cofactor.  To date, cytochrome c is 
the only known factor that can trigger the formation of an active caspase-9 
holoenzyme complex, known as the apoptosome (Liu et al., 1996).  The 
apoptosome forms after cytochrome c binds Apaf-1, and triggers a 
conformational change that permits recruitment of caspase-9 to Apaf-1 via 
homotypic interactions.  This functional unit oligomerizes into a wheel-
shaped structure with seven-fold symmetry (Acehan et al., 2002).  The 
formation of an apoptosome is energy dependent and requires both an ADP-
ATP nucleotide exchange and hydrolysis of ATP by the ATPase activity of 
Apaf-1 (Riedl et al., 2005).  Apaf-1 is an allosteric activator of caspase-9 
that stimulates its activity toward caspase-3 by several orders of magnitude 
(Rodriguez and Lazebnik, 1999).  While dimerization is necessary for 
caspase-9 activity (Shiozaki et al., 2003), the intra-chain cleavage that 
occurs in the apoptosome is largely dispensable for its activity.  Formation 
of an apoptosome appears to be a prerequisite for the recruitment and 
activation of caspase-3 (Bratton et al., 2001).  Although CED-4 does not 
appear to require a cofactor like cytochrome c, it does oligomerize to 
promote CED-3 processing and activation (Seshagiri and Miller, 1997b; 
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Yang et al., 1998).  
The best evidence for a linear cytochrome c-Apaf-1-caspase-9-
caspase-3 pathway comes from studies using mouse embryonic fibroblasts 
(MEFs) from knockout animals.  Cytochrome c is the only known activator 
of Apaf-1 following DNA damage in MEFs.  After UVC irradiation, the 
apoptosome does not oligomerize in MEFs harboring a mutant cytochrome c 
allele that retains respiratory functions but has a diminished capacity to bind 
Apaf-1 (Hao et al., 2005).  Caspase-3 cleavage is not seen and the cells are 
very resistant to apoptosis.  When compared directly, this phenotype is 
slightly less severe than in cells lacking Apaf-1, which suggests that other 
activators of Apaf-1 may exist.  Alternatively, it is possible that the mutant 
cytochrome c retains some residual capacity to activate Apaf-1.  Caspase-9 
cleavage is almost entirely impaired in Apaf-1-null MEFs (Ho et al., 2004), 
and caspase-3 cleavage is essentially absent in caspase-9-null MEFs (Kuida 
et al., 1998) and ES cells (Hakem et al., 1998). 
Biochemical studies and knockouts of individual components (mostly 
in MEFs) order initiator and effector caspases in a cascade downstream of 
mitochondria, but this may be an overly simplistic view.  Mice doubly 
deficient for caspase-3 and caspase-7 display postnatal lethality and 
defective heart development, while MEFs are broadly resistant to 
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mitochondrial and death receptor apoptosis (Lakhani et al., 2006).  This 
finding argues that these caspases are required for apoptosis in MEFs and 
probably other cells.  Remarkably, however, many steps that are presumed 
to act upstream of caspase activation are delayed in these double-knockout 
MEFs.  For instance, during apoptosis in double-knockout MEFs, 
mitochondrial integrity is largely maintained; BAX translocation is 
diminished; and cytochrome c is released more slowly during apoptosis 
(Lakhani et al., 2006).  These studies argue that mitochondria may function 
as amplifiers of an initial apoptotic signal in certain cell types.  
There are probably other cell death pathways in thymocytes apart 
from the known apoptotic programs.  Thymocytes deficient for caspases-3 
and -7 are resistant (though not completely) to mitochondrial apoptotic 
stimuli, but die readily through receptor pathways.  Thymocytes lacking the 
pro-apoptotic function of cytochrome c mount normal apoptotic responses to 
diverse stimuli, even though apoptosome formation does not occur; Apaf-1-
null thymocytes are more broadly resistant (Hao et al., 2005).   Although this 
cytochrome c mutant probably retains some residual capacity to activate 
Apaf-1, it is very likely that thymocytes have redundant death programs that 
require further elucidation.  Caspase activation need not proceed directly 
from initiator to effector caspases; there is evidence that caspase-6 may 
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activate caspase-8, the caspase thought to be responsible for initiating death 
receptor apoptosis (see below)(Murphy et al., 2004). 
1.4.2 Activation through death receptors 
 
A second pathway leading to apoptosis is triggered through cell 
surface receptors that signal to activate caspases.  Mouse and human cells 
express a variety of receptors in the TNF-α (tumor necrosis factor α) 
receptor superfamily, which includes Fas (APO-1/CD95).  Death receptors 
span the plasma membrane, extending an extracellular cysteine-rich motif 
that binds cognate ligands and a cytoplasmic tail that signals to other factors.  
The expression of receptors is often regulated; for example, resting B-cells 
express low levels of the Fas receptor, but upregulate the receptor in the 
presence of cytokines or endotoxins (Watanabe et al., 1995).   Death ligands 
such as Fas ligand (FasL) are trimers, and can be membrane bound on 
signaling cells or cleaved by extracellular proteases to become soluble 
factors.  These ligands are usually expressed on the surface of activated T-
cells and natural killer T-cells, where they have a cytotoxic function during 
immune responses (Suda et al., 1993). 
Fas signaling is well characterized and also considerably simpler than 
the TNF-α pathway (discussed in Chapter 5).  The Fas receptor was 
identified as the molecular target of an antibody (anti-APO-1) that induces 
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apoptosis in malignant lymphocytes (Trauth et al., 1989).  The antibody 
functions as a FasL agonist that aggregates the receptor into homotrimers 
(Siegel et al., 2000), and triggers assembly of a DISC (death inducing 
signaling complex) on the cytosolic face of the receptor (Kischkel et al., 
1995).  The DISC forms when the receptor recruits the adaptor protein 
FADD (Fas-associated death domain) through homotypic DD interactions.  
FADD also contains death effector domains (DEDs) that recruit caspase-8 
(also caspase-10 in human cells), also through homotypic interactions. 
Caspase-8 appears to require a DISC to dimerize and activate, because the 
isolated procaspase is an inactive monomer (Donepudi et al., 2003).  
Procaspase-8 is cleaved after binding the DISC, possibly by auto-proteolysis 
after changing conformation (Medema et al., 1997), but all of the subunits 
remain associated (Lavrik et al., 2003).  The DISC appears to promote 
caspase-8 dimerization and cleavage, but cleavage may be dispensible for 
activity (Donepudi et al., 2003).  Caspase-3 is cleaved and activated by 
caspase-8 in the DISC.  Caspase-8 initiates Fas-dependent apoptosis in 
MEFs; caspase-8-null cells are not killed by receptor ligation (Varfolomeev 
et al., 1998).  Caspase-8 activation is regulated by DISC assembly and a 
competitor, c-FLIP (cellular FLICE [caspase-8]-like inhibitor protein).  c-
FLIP exists as a short form (c-FLIPS)  with two DED domains, and a long 
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form (c-FLIPL) that resembles caspase-8 with two DED domains and an 
non-functional active site.  c-FLIPL may function as a dominant-negative 
inhibitor of caspase-8 activation in the DISC, and its roles are discussed in 
further detail in Chapter 5.  
1.5 Regulation of cell death by anti-apoptotic proteins 
 
Since the core apoptotic machinery appears to be universally 
expressed in most cells, it is not surprising that the steps leading to caspase 
activation are very tightly controlled.  One such strategy involves the 
sequestration of pro-apoptotic factors in mitochondria.  For example, 
cytochrome c, the only known activator of Apaf-1, is normally resident in 
the intermembrane space of mitochondria.  The steps leading to translocation 
of cytochrome c from mitochondria to the cytosol are regulated by the BCL-
2 family of proteins.  Initially, the anti-apoptotic function of BCL-2 was 
apparent from its functional similarity to the CED-9 protein from C. elegans, 
which can prevent death.  Early studies showed that BCL-2 localizes to 
mitochondria and prevents many manifestations of apoptosis without 
promoting cell division (Hockenbery et al., 1990). 
The molecular cloning of BCL-2 led to the identification of an 
extended family of homologues that include anti- and pro-apoptotic 
constituents.  The principal anti-apoptotic family members are BCL-XL 
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(Boise et al., 1993), MCL-1 (Kozopas et al., 1993), A1 (Choi et al., 1995) 
and BCL-W (Gibson et al., 1996).  BAX was the first pro-apoptotic family 
member and identified as a binding partner of BCL-2 (Oltvai et al., 1993), 
while the related BAK was cloned by homology (Kiefer et al., 1995).  Anti- 
and pro-apoptotic BCL-2 family members are classified by their domain 
organizations: factors that inhibit death seem to have four BH (BCL-2 
homology) domains (BH1-4), while pro-death members have three (BH1-3).  
These factors can bind each other by virtue of a BH1-3 binding pocket on 
anti-apoptotic BCL-2 proteins that accommodates the BH3 domain of pro-
death factors (Sattler et al., 1997). 
BAX and BAK appear to require conformational changes to engage 
anti-apoptotic BCL-2 proteins and promote death (Sattler et al., 1997).  BAX 
is present as a cytosolic or perimitochondrial monomer in healthy cells, but 
changes conformation, oligomerizes and inserts into mitochondrial 
membranes before apoptosis (Suzuki et al., 2000).  BAK also shifts 
conformations and associates with mitochondria prior to apoptosis.  The 
combined activation of BAX and BAK lead to release of pro-apoptotic 
factors like cytochrome c from mitochondria into the cytosol (Wei et al., 
2001).  How this happens is unknown, but recombinant BAX and BAK are 
capable of forming pores in isolated vesicles (Korsmeyer et al., 2000).  
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While mice deficient for either BAX or BAK are viable, the compound 
knockout results in neonatal lethality with a very high penetrance (Lindsten 
et al., 2000).  This is probably because BAX and BAK double knockout cells 
are virtually resistant to apoptotic stimuli that involve mitochondrial factors 
(Wei et al., 2001). 
Although it is still unclear how BAX and BAK are activated, their 
pro-death functions appear to depend on factors from a third class of BCL-2 
family members that harbor only the third BH domain (“BH3-only”).  This 
family has grown to include a large number of BH3-only proteins since the 
identification of the founding member, BID (Wang et al., 1996).  The wide 
variety of regulatory steps that control individual BH3-only proteins stresses 
their roles in activating apoptosis in response to distinct stimuli.  For 
example, the BH3-only genes PUMA (Nakano and Vousden, 2001) and 
NOXA (Oda et al., 2000) are upregulated by p53 following genotoxic stress; 
PUMA is the key transducer of apoptotic signaling to BAX and BAK after 
DNA damage in many cell types (Villunger et al., 2003).  BIM is the key 
mediator of apoptosis triggered by cytokine withdrawal, and has a role in 
promoting the death of autoreactive lymphocytes during development 
(Bouillet et al., 1999).  Additionally, the BH3-only protein BMF is poised to 
trigger apoptosis when cells detach from extracellular substrata by its 
 18 
association with myosin bundles (Puthalakath et al., 2001).  The BH3-only 
protein BID is required for death receptor apoptosis in cells like hepatocytes, 
where it amplifies the apoptotic signal through the mitochondrial pathway  
(Yin et al., 1999).  BID is cleaved by caspase-8 during death receptor 
signaling; truncated BID inserts into mitochondrial membranes to promote 
BAX and BAK oligomerization and mitochondrial relocalization, which in 
turn promotes cytochrome c release (Desagher et al., 1999). 
Individual BH3-only proteins bind distinct but overlapping subsets of 
pro- and anti-apoptotic BCL-2 proteins (Chen et al., 2005).  This led to a 
hypothesis that certain BH3-only proteins like BIM and BID function as 
“activators” that directly activate BAX and BAK, while others like BAD and 
NOXA act as “sensitizers” by displacing anti-apoptotic BCL-2 factors from 
the activators (Letai et al., 2002).  An alternative hypothesis stresses the 
point that BH3-only factors can activate apoptosis indirectly by inhibiting 
the anti-apoptotic BCL-2 proteins (Willis et al., 2005).  The proposed 
mechanisms are not necessarily exclusive, and the interactions that lead to 
mitochondrial membrane permeabilization and cytochrome c release clearly 
require further research.  
The central logic behind the apoptotic pathway appears throughout 
multicellular animals.  C. elegans relies on a streamlined version of the 
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pathway described above.  The C. elegans genome harbors an anti-apoptotic 
BCL-2 gene, ced-9 (Metzstein et al., 1998), and at least two BH3-only 
genes, egl-1 and ced-13 (Schumacher et al., 2005).  ced-13 is 
transcriptionally upregulated in the germline by a p53 homologue, while egl-
1 is more broadly utilized in the soma; both act pro-apoptotically by 
preventing CED-9 from inhibiting CED-4 (Schumacher et al., 2005; Yan et 
al., 2005). 
1.6 IAPs: negative regulators of caspases 
 
In most cells, caspases are subject to at least two forms of negative 
control.  The activation steps are regulated in the mitochondrial and receptor 
routes to apoptosis: BCL-2 proteins determine whether mitochondrial factors 
like cytochrome C translocate to the cytosol to activate caspases, while the 
death receptor pathway requires ligands to activate initiator caspases.  
Furthermore, caspases are subject to negative regulation by inhibitors.  One 
important group of negative caspase regulators includes the Inhibitor of 
Apoptosis Proteins (IAPs) (Miller, 1999).  The first IAPs were identified in a 
genetic complementation screen for genes in the baculovirus genome that 
could substitute for loss of p35, then the only known inhibitor of cell death 
in virally infected insect cells (Birnbaum et al., 1994; Crook et al., 1993).  
This effort led to the identification of iap in the genome of Autographa 
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californica nuclear polyhedrosis virus, as well as homologues like Op-iap 
from Orgyia pseudotsugata virus (Clem and Miller, 1994; Crook et al., 
1993).  Baculovirus IAPs are characterized by a unique zinc finger motif of 
about 80 amino acids, later known as the BIR (for baculovirus IAP 
repeat)(Crook et al., 1993).  Insights into baculoviral IAP function came 
from the observation that Op-IAP inhibits the processing and activation of 
an insect effector caspase during viral infection (Seshagiri and Miller, 
1997a).  Subsequent work showed that BIR domains are principally involved 
in binding to and inhibiting caspases (Takahashi et al., 1998). 
The discovery of related genes in insect and mammalian genomes 
suggested that IAPs might be part of a larger regulatory scheme (Salvesen 
and Duckett, 2002; Vaux and Silke, 2005). The cellular IAPs (cIAPs) 1 and 
2 were identified biochemically in human cells as binding partners of the 
TRAF2 protein in TNF-α apoptosis (see introduction to Chapter 5)(Rothe et 
al., 1995), while the X-chromosome-linked IAP (XIAP) was identified by 
homology to other IAPs  (Duckett et al., 1996).  In mammals, the other BIR-
containing proteins are ML-IAP (melanoma IAP) (Vucic et al., 2000), 
Bruce/apollon (Chen et al., 1999), Survivin (Ambrosini et al., 1997), and a 
testis-specific IAP (ts-IAP) present in great apes (Richter et al., 2001).  All 
of these IAPs bear at least one BIR, while cIAP1, cIAP2, XIAP ts-IAP, and 
 21 
ML-IAP harbor RING domains.  cIAP1 and cIAP2 also have a CARD 
domain. The Drosophila genome harbors two IAPs, DIAP1 and DIAP2, 
with two BIR domains and a RING motif.  The C. elegans genome has a 
Survivin-like gene, but Survivin probably does not function in cell death 
(Lens et al., 2006).  The lack of any apparent IAPs in C. elegans might 
reflect the need for expanded control over caspases in more complex or 
longer-lived organisms. 
1.6.1 Inhibition of caspases by direct binding 
 
The discovery that XIAP can bind and inhibit caspases with BIR 
domains partly explains why IAP expression prevents death (Deveraux et 
al., 1997; Takahashi et al., 1998).  XIAP is the most studied mammalian 
IAP, probably because it is the best inhibitor of caspases in vitro (Eckelman 
and Salvesen, 2006).  XIAP can directly bind and inhibit caspases through 
BIR domains present in triplicate in the amino-terminal half of the protein.  
Deletion mapping and structural studies reveal how XIAP can inhibit 
different caspases.  A peptide sequence that includes the second BIR domain 
binds to and inhibits active caspases-3 and -7 by a common mechanism 
(Chai et al., 2001a; Riedl et al., 2001; Sun et al., 1999).  The initial structural 
studies revealed that a short peptide sequence on the immediate amino-
terminal side of BIR2 is necessary for caspase inhibition.  This section of the 
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linker between BIR1 and BIR2 forms a hydrophobic binding pocket that 
spans the caspase catalytic groove in the opposite orientation from caspase 
substrates.  This interaction precludes access to the caspase active site.  
Subsequent studies have shown that the BIR2 makes additional contacts 
with caspases-3 and -7 that stabilize the interactions (Scott et al., 2005).  
Two closely related IAPs, cIAP1 and cIAP2, can bind caspases-3 and -7 but 
inhibit their enzymatic activity very poorly in vitro (Eckelman and Salvesen, 
2006).  The differences appear to lie in the linker region between BIR1 and 
BIR2, because replacing the cIAP1 or cIAP2 linker with the XIAP linker 
increases caspase inhibition. 
XIAP inhibits caspase-9 by a different mechanism altogether 
(Shiozaki et al., 2003).  XIAP associates with the apoptosome (Bratton et al., 
2001), where the XIAP BIR3 makes a large continuous contact with a 
caspase-9 monomer.  This interaction simultaneously maintains the caspase 
as an inactive monomer and precludes the active site from adopting a 
productive conformation.  Sequestering caspase-9 as a monomer is 
especially inhibitory because caspases must dimerize to be active (Shi, 
2002b).  XIAP BIR3 forms a hydrophobic binding pocket that makes 
additional contacts with the amino-terminal tetrapeptide of the caspase-9 
small subunit known as the IAP binding motif (IBM).  Although cIAP1 and 
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cIAP2 also bind the caspase-9 IBM through a similar pocket in BIR3, they 
lack a suitable interface for holding caspase-9 in a monomeric state.  This 
observation probably explains why these IAPs are poor inhibitors of 
caspase-9 (Eckelman and Salvesen, 2006). 
1.6.2 Inhibition of caspases through ubiquitination 
 
In addition to BIR domains that can bind and inhibit caspases, many 
IAPs also contain a RING (really interesting new gene) domain that bestows 
ubiquitin-ligase functions.  RING domains are found in diverse proteins and 
impart substrate specificity to the ubiquitin system (Joazeiro and Weissman, 
2000).  The ubiquitin system is the principal mechanism for actively 
regulating the abundance of proteins in eukaryotic cells (Glickman and 
Ciechanover, 2002).   Ubiquitin-ligases can target proteins for degradation 
by assembling ubiquitin polymers on specific substrates.  Polyubiquitin 
chains are assembled through the sequential activity of three highly 
conserved classes of enzymes.  In the first step, the E1 ubiquitin-activating 
enzyme forms a high energy intermediate between an active site cysteine 
side chain and a ubiquitin monomer.  This step requires energy in the form 
of ATP.  The activated ubiquitin is then transferred to an active site cysteine 
in the E2 ubiquitin-conjugating enzyme.  The E3 ubiquitin-ligase 
simultaneously binds its cognate E2 and the substrate to be ubiquitinated, 
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and juxtaposes the two to promote ubiquitin transfer between the E2 and an 
internal lysine on the substrate.   In the case of RING E3s, the ubiquitin is 
transferred without forming a RING-ubiquitin intermediate, as there are no 
catalytic residues.  The RING may serve as an allosteric activator of the E2, 
or perhaps by forming a scaffold to structurally coordinate ubiquitin transfer 
(Glickman and Ciechanover, 2002).  Generally, eukaryotic genomes harbor 
two E1 enzymes and several hundred E2s; mammalian genomes contain 
possibly as many as 1000 RING E3s.  This observation highlights the central 
role that ubiquitination plays in regulating diverse cellular processes. 
The way in which a RING ubiquitinates its substrate influences the 
outcome of ubiquitination (Hochstrasser, 2006).  The majority of RINGs 
studied so far appear to form a polyubiquitin chain on their substrates 
through iterative addition of ubiquitins through Lys48 linkages (Pickart and 
Eddins, 2004).  A typical polyubiquitin chain contains more than a dozen 
ubiquitin moieties, but extension of a Lys48 ubiquitin chain to four or more 
subunits appears to constitute a minimal recognition sequence for the 
proteasome, the elaborate protease complex that proteolyses ubiquitinated 
substrates (Thrower et al., 2000).  Alternatively, a RING can mono-
ubiquitinate a substrate, or form polyubiquitin linkages with different 
topologies that may not necessarily lead to degradation by the proteasome 
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(Vaux and Silke, 2005).  An example of this is the Lys63-linked 
polyubiquitin chain assembled on RIP1 and TRAF2 to activate the canonical 
NF-κB pathway (discussed below in the introduction to Chapter 5).  
Additionally, ubiquitin was discovered as a covalent histone modification 
(Goldknopf and Busch, 1975) that does not promote degradation by the 
proteasome.   Many aspects of the ubiquitin system are mysterious.  For 
instance, it is not clear exactly how a RING E3 can activate its cognate E2 to 
promote ubiquitin transfer because the E2 does not appear to change 
conformation after binding an E3 (Hochstrasser, 2006). 
IAP RINGs have been studied thoroughly in Drosophila, where 
DIAP1 functions as an E3-ubiquitin ligase for regulating cell death and 
survival.  This includes targeting the caspase-9 ortholog DRONC for 
degradation by the proteasome in living cells, and promoting self-
conjugation and DIAP1 degradation under apoptotic conditions (Ryoo et al., 
2002; Ryoo et al., 2004; Wilson et al., 2002).  Loss of DIAP1 RING 
function leads to late embryonic lethality accompanied by massive levels of 
apoptosis, which closely mimics a complete loss of DIAP1 function (Goyal 
et al., 2000; Lisi et al., 2000).  Point mutations that inactivate RING 
ubiquitin-ligase function do not preclude DIAP1 from binding the initiator 
caspase DRONC, but they do prevent polyubiquitination of DRONC 
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(Wilson et al., 2002).  In principal, loss of an anti-apoptotic function of the 
DIAP1 RING (e.g., polyubiquitinating DRONC) could be mitigated by the 
concurrent loss of a pro-apoptotic function (e.g., promoting self-conjugation 
and degradation).  In the absence of DIAP1 RING function, however, 
DIAP1 is stabilized and its protein levels are increased, but the net outcome 
for most cells is still excessive cell death due to highly elevated DRONC 
levels (Ryoo et al., 2004). 
Among mouse IAPs, XIAP, cIAP1, cIAP2 and ML-IAP all have 
RING domains, but their functions in vivo are largely unknown (Vaux and 
Silke, 2005).  The RING domains of XIAP and cIAP1 regulate the 
abundance of these proteins during apoptosis in primary mouse thymocytes 
(Yang et al., 2000).  XIAP and cIAP1 can both self-conjugate polyubiquitin 
chains in vitro.  This is the first function assigned to IAP RINGs, and it is 
hypothesized to underlie the death of thymocytes because IAP 
downregulation occurs before many manifestations of apoptosis (Yang and 
Li, 2000).  Consistent with this notion, a RING-deleted XIAP is stably 
expressed in a mouse T-cell hybridoma and imparts resistance to diverse 
death stimuli (Yang et al., 2000).  There is evidence that the XIAP RING 
can regulate the abundance of active caspase-3 subunits during apoptosis 
(Suzuki et al., 2001), in a manner reminiscent of how DIAP1 RING 
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regulates DRONC (Wilson et al., 2002).  These experiments are difficult to 
interpret because they involve ectopic expression of active-site mutants of 
caspase-3, and XIAP binds caspase-3 at its active site (Riedl et al., 2001).  
There are also in vitro and overexpression data implicating XIAP RING in 
regulating the abundance of the large subunit of active caspase-9 (Morizane 
et al., 2005) and active caspase-7 (Creagh et al., 2004).  These experiments 
are also difficult to interpret because it is unclear how much of the observed 
changes are owing to overexpression artifacts.  
1.7 IAP antagonists 
 
Genetic studies in Drosophila identified a novel class of IAP 
antagonists that derepress caspases, at least in part by competitively 
displacing them from IAPs.  The three founding members of the IAP 
antagonist family, Reaper, Hid (head involution defective) and Grim, were 
discovered as three tightly linked loci in a genomic region required for 
initiating all cell death during Drosophila development (White et al., 1994).  
Reaper, Hid and Grim function as integrators that relay diverse pro-apoptotic 
stimuli, ranging from developmental cues to genotoxic damage, to trigger 
cell death.  All three proteins share a structurally conserved N-terminal IAP-
binding-motif (IBM) that can bind BIR domains (Shi, 2002a).  The IBM 
appears to be the basis for caspase derepression, since IAP antagonists can 
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liberate caspases from IAPs by binding BIR domains more tightly (Shi, 
2002b; Srinivasula et al., 2001).  
IAP antagonists appear in a central position to dictate the outcome of 
DIAP1 E3 activity.  Expression of Reaper depletes DIAP1 through RING-
dependent autoubiquitination, leading to apoptosis in the wing imaginal disc 
and other tissues (Ryoo et al., 2002).  Furthermore, Ubcd1, which encodes a 
cognate E2 for DIAP1 RING, genetically interacts with DIAP1 and is 
required for Reaper-dependent apoptosis (Ryoo et al., 2002).  Structural 
studies offer some insights into how IAP antagonists might regulate DIAP1 
RING ubiquitination of caspases (Chai et al., 2003).  DRONC binds DIAP1 
BIR2 using a peptide sequence that maps between the prodomain and the 
large subunit, but is distinct from the typical IBM interface.  The DRONC 
and Reaper/Hid/Grim binding sites overlap, however, which allows IAP 
antagonists to compete for BIR2 using tighter binding affinities (Wu et al., 
2001).  In this manner, IAP antagonists liberate DRONC and prevent DIAP1 
RING from ubiquitinating it.  Although DIAP1 has intrinsic tendency to 
autoubiquitinate in vitro, it is still unclear how IAP antagonists stimulate this 
phenomenon during apoptosis.  Perhaps DIAP1 has no other local substrate 
when bound to a small IAP antagonist like Reaper (65 amino acids). 
Mammalian genomes harbor many genes that bear superficial 
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similarities to fruit fly IAP antagonists.  Smac (second mitochondrial 
activator of apoptosis) was identified biochemically as a factor present in the 
detergent-soluble membrane fraction that promotes caspase-3 activation in 
cellular extracts (Du et al., 2000); the same protein was identified as a 
binding partner of XIAP, and named DIABLO (direct IAP binding protein 
with low pI) by a second group (Verhagen et al., 2000).  Smac is a 
homodimer that localizes to the mitochondria in healthy cells and egresses to 
the cytosol during apoptosis, where it antagonizes IAPs and promotes 
caspase activation.  The amino-terminal tetrapeptide motif (AVPI) of mature 
Smac shares sequence similarity to the amino-termini of fruit fly IAP 
antagonists (Reaper: AVAF; Hid: AVPR; Grim: AIAY).  It is also very 
similar to the IBM of the caspase-9 small subunit (human: ATPF; mouse: 
AVPY), which suggests a mechanism for how Smac can competitively 
liberate caspase-9 from XIAP in the apoptosome (Srinivasula et al., 2001).  
Indeed, the crystal structure of a XIAP/Smac complex confirms that Smac 
binds the same hydrophobic IBM-binding grooves in BIR2 (Chai et al., 
2000) and BIR3 (Liu et al., 2000; Wu et al., 2000) where caspases also bind 
(Scott et al., 2005; Shiozaki et al., 2003).  While monomeric Smac suffices 
to liberate caspase-9 from BIR3, dimeric Smac appears to be required to 
derepress effector caspases probably because these caspases make additional 
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contacts with the BIR2 linker in addition to the BIR2 IBM pocket (Chai et 
al., 2000; Gao et al., 2007).  IBM binding grooves appear to have a 
conserved function throughout evolution, as they are found in DIAP1 as well 
(Wu et al., 2001).  The IBMs of Grim and Hid bind DIAP1 BIR2 (the 
counterpart to XIAP BIR3) similarly to how Smac binds XIAP (Chai et al., 
2003).  Another mammalian IAP binding protein, Omi, is a serine protease 
known to compete with XIAP for binding to caspases using similar 
principles (Vaux and Silke, 2003).  ARTS (apoptosis related protein in TGF-
β signaling pathway) is another IAP antagonist that can target XIAP 
(Gottfried et al., 2004; Larisch et al., 2000). Recently, a panel of other IAP 
antagonists have been identified as XIAP binding partners, and all appear to 
have IBM motifs (Verhagen et al., 2007).  The functions of these proteins 
during apoptosis are largely unknown. 
IAP antagonists function pro-apoptotically and their activity must be 
regulated to prevent spurious induction of cell death programs.   Reaper, for 
example, is probably only present in cells that are doomed to die (Steller et 
al., 1994).  Transcriptional activation of the Reaper locus appears to underlie 
many forms of apoptosis in Drosophila, ranging from developmental cell 
death (Jiang et al., 2000; Lohmann et al., 2002) to apoptosis following 
genotoxic damage (Brodsky et al., 2000; Nordstrom et al., 1996).  Hid is 
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broadly expressed in most Drosophila cells, including viable cells, but is 
negatively regulated by survival signaling through the Ras pathway at the 
transcriptional (Kurada and White, 1998) and post-translational levels 
(Bergmann et al., 1998).  Remarkably, all of the known mammalian IAP 
antagonists seem to localize to mitochondria and are released to the cytosol 
during apoptosis (Vaux and Silke, 2003).  This finding emphasizes the logic 
behind sequestering pro-apoptotic factors in distinct subcellular 
compartments to discourage accidental cell death. 
It is unclear if IAP antagonists play a central role in regulating IAP 
abundance in mammals as they do in Drosophila.  Ectopic expression and in 
vitro experiments provide all of evidence that IAP antagonists can regulate 
IAP abundance.  Ectopic expression of active (e.g., with a cleaved amino-
terminal mitochondrial localization sequence) Smac efficiently depletes 
cIAP1 and cIAP2, but not XIAP, in HeLa cells.  Expression of active Smac 
may actually antagonize XIAP E3 activity (Creagh et al., 2004; Silke et al., 
2004).   Similarly, small-molecule IAP antagonists deplete cIAP1 and cIAP2 
efficiently but leave XIAP expression relatively unchanged (Varfolomeev et 
al., 2007; Vince et al., 2007).  ARTS might function similarly as fruit fly 
IAP antagonists, because expression of ARTS can deplete XIAP from cells 
(Gottfried et al., 2004). 
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Drosophila IAP antagonists have apoptotic functions in mammalian 
cells.  Expression of Grim in human 293T cells depletes XIAP efficiently 
but does not induce apoptosis (Silke et al., 2004); however, expressing Hid 
depletes XIAP (A. Kelkar, personal communication) and correlates with 
apoptotic cell death that can be inhibited by IAPs in Hela cells (Haining et 
al., 1999).  Reaper also functions in mammalian cells by stimulating XIAP 
autoubiquitination (Holley et al., 2002).   Some of the mammalian IAP 
antagonists probably do function like fruit fly antagonists because the 
functions of Reaper, Hid and Grim are conserved.  It is clear that the biology 
of IAP antagonists requires more investigation. 
1.8 Mouse models of IAP function 
 
Flies lacking DIAP1 function die as embryos because of ubiquitous 
apoptosis (Goyal et al., 2000; Lisi et al., 2000). Surprisingly, however, 
individual genetic deletions of XIAP (Harlin et al., 2001; Olayioye et al., 
2005), cIAP1 (Conze et al., 2005), or cIAP2 (Conte et al., 2006) by 
homologous recombination result in an essentially normal mouse on 
commonly used genetic backgrounds (C57BL/6 or 129/Ola).  XIAP-null 
females show delayed lobuloalveolar development accompanied by reduced 
milk protein synthesis, but this effect does not seem related to apoptosis 
(Olayioye et al., 2005).  The roles of individual IAPs in regulating apoptosis 
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during development may be masked by a combination of functional 
redundancy and compensatory upregulation.  For example, there is evidence 
for IAP cross-regulation and possible redundancy in cells from the cIAP1-
null mouse (Conze et al., 2005).  cIAP2 levels increase post-translationally 
in cIAP1-null cells because cIAP1 negatively regulates the abundance of 
cIAP2 through ubiquitination and proteasomal degradation.  XIAP 
expression is unaltered in cells from cIAP1-null mice, however, and its 
expression levels have yet to be addressed in cIAP2-null cells.  cIAP2-null 
mice are resistant to endotoxic shock by bacterial lipopolysaccharide 
administration (Conte et al., 2006).  This phenotype may arise because 
macrophages from cIAP2-null mice are sensitized to Fas apoptosis following 
endotoxic shock; cIAP2 expression increases by about 30-fold in endotoxin 
treated WT cells, which may explain why these cells normally survive. 
The role of functional redundancy could be addressed by generating 
compound mutant mice by interbreeding existing knockouts.  The relatively 
unstudied members of the IAP family should be included in this effort.  For 
example, ML-IAP harbors a RING ubiquitin-ligase domain and a BIR 
domain that binds caspases weakly but Smac strongly (Vucic et al., 2002).  
To our knowledge, ML-IAP has not been knocked out in mice.  Another 
IAP, Bruce/Apollon, is unique not only for its size (528 kDa) but also 
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because it harbors an E2 ubiquitin-conjugating domain that can participate in 
polyubiquitinating Smac and caspase-9 when all are ectopically expressed 
(Hao et al., 2004).  The functions of Bruce in vivo are hard to discern 
because the three knockout mice generated so far (two by gene targeting and 
one by gene trapping) yield conflicting results.  All three Bruce-null mice 
are lethal in utero, though not at the same developmental stages (Hao et al., 
2004; Lotz et al., 2004; Ren et al., 2005).  One group (Ren et al., 2005) 
noted increased apoptosis in situ that associated with lethality in their gene-
trapped knockout, while the others (Hao et al., 2004; Lotz et al., 2004) did 
not observe appreciable differences in death in gene-targeted embryos.  Two 
groups (Hao et al., 2004; Ren et al., 2005) describe increased sensitivity to 
apoptotic stimuli in embryonic fibroblasts, while a third group reports no 
difference (Lotz et al., 2004).  Bruce has other functions unrelated to 
apoptosis (Pohl and Jentsch, 2008), which is not surprising given the size of 
the protein.  It is intriguing that the mutant with the most severe apoptosis 
phenotype (Ren et al., 2005) retains the BIR but not the E2 domain, while 
the other two mice lacked the entire gene.  Studies on the fly homologue, 
dBruce, highlight the central importance of E2 domain in enhancing Reaper 
and Grim-dependent death (Vernooy et al., 2002). Perhaps the presence of 
the BIR is sufficient to subvert any compensatory mechanisms in place in 
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mouse cells.  More work is clearly needed to address the role of Bruce and 
ML-IAP in relation to other mammalian IAPs. 
XIAP-null thymocytes, splenocytes and embryonic fibroblasts die 
normally in response to many different apoptotic stimuli; however, post-
mitotic cells cultured from XIAP-null mice show some apoptosis phenotypes 
that offer some deep insights into tissue-specific regulation by XIAP.  
Sympathetic neurons (Potts et al., 2003) and cardiomyocytes (Potts et al., 
2005) from XIAP-null mice rapidly die by apoptosis after microinjection of 
cytochrome c, while cells from WT mice are completely insensitive.  Dermal 
fibroblasts from XIAP-null and WT mice are equally sensitive to cytochrome 
c injection, however.  XIAP inhibition is also necessary for apoptosis to 
occur following nerve growth factor withdrawal in cultured sympathetic 
neurons (Potts et al., 2003).  Similar observations are seen in neuronally 
differentiated PC12 pheochromocytoma cells, which require inhibition of 
XIAP to die (Perrelet et al., 2002; Vyas et al., 2004).  It is unknown if XIAP-
null mice are prone to neurodegenerative diseases. 
These observations show that XIAP is a non-redundant regulator of 
apoptosis in certain post-mitotic cells, some of which (e.g., neurons) can 
persist throughout life.  Intriguingly, the expression levels of Apaf-1 are 
inversely related to how well XIAP can inhibit caspases and apoptosis after 
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cytochrome c release (Potts et al., 2005).  Downregulation of Apaf-1 seems 
to be an effective strategy employed by post-mitotic cells to ensure that 
XIAP remains an effective inhibitor of caspases.  Proliferative cells 
represent a greater danger to the organism as a whole; perhaps it is not 
surprising that there are alternate routes to apoptotic and non-apoptotic death 
that may be independent of IAPs.   
The IAP antagonists Smac and Omi have been disrupted individually 
and together in the mouse (Martins et al., 2004; Okada et al., 2002).  Smac-
null mice are viable and fertile.  Caspase-3 activation is impaired in vitro in 
Smac-null fibroblast lysates; however, apoptosis occurs normally in cultured 
primary and transformed fibroblasts, embryonic stem cells, hepatocytes and 
thymocytes (Okada et al., 2002).  A role for Smac in apoptosis has emerged 
by comparing apoptosis in embryonic myoblasts and fibroblasts from Smac- 
and Apaf-deficient mice (Ho et al., 2007).  XIAP is expressed at lower levels 
in myoblasts than fibroblasts.  Release of Smac into the cytosol during 
mitochondria-dependent apoptosis is sufficient to neutralize XIAP in 
myoblasts, and caspase activation and apoptosis occur even the absence of 
Apaf-1.  Simultaneous deletion of Smac and Apaf-1 is necessary to block 
apoptosis in myoblasts.  This type of regulation does not occur in fibroblasts 
because of the elevated level of XIAP; however, neutralization of XIAP by 
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small-molecule inhibitors allows apoptosis to occur in the absence of Apaf-1.  
These experiments reveal two independent pathways that can activate 
caspases and apoptosis in mammalian cells: one depends on Apaf-1, and the 
other is regulated by XIAP and IAP antagonists.  Similar logic underlies 
caspase activation in Drosophila (Zhou et al., 1999). 
The Omi knockout mouse suffers from a neurodegenerative disorder 
(Martins et al., 2004); however, this phenotype is owing to loss of Omi 
serine protease activity, rather than loss of IAP inhibitory function (Jones et 
al., 2003).  Compound deletion of Smac and Omi does not exacerbate this 
phenotype.  A physiological role of these proteins for regulating IAPs 
remains to be established, but this is possibly masked due to functional 
redundancy and the presence of additional IAP-antagonists.  Indeed, there 
are far more potential IAP antagonists than IAPs in mammalian genomes 
(Vaux and Silke, 2003; Verhagen et al., 2007).  Loss of Sept4, the locus 
encoding ARTS, results in male sterility accompanied by increases in XIAP 
expression in the testis (Kissel et al., 2005). ARTS can regulate XIAP 
expression by promoting auto-ubiquitination and degradation by the 
proteasome (Gottfried et al., 2004).  Furthermore, loss of ARTS worsens 
prognosis on the Eµ-Myc lymphoma background corresponding to decreased 
apoptosis in vivo (M. García-Fernández and H. Steller, unpublished data).  
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1.9 Roles of IAPs outside of apoptosis 
 
Many IAPs may be multifunctional proteins with roles distinct from 
regulating caspases and apoptosis.  Overexpression of IAPs can activate 
diverse signaling pathways, including JNK, TGF-β and NF-κB (Lewis et al., 
2004), but it is unclear if these are physiological observations. XIAP and 
cIAP1 are reportedly positive regulators of the NF-κB pathway downstream 
of the TNF-α cytokine, as cells with silenced expression of XIAP (Gaither et 
al., 2007) or cIAP1 (Tang et al., 2003) cells show signs of reduced NF-κB 
activity.  Primary cIAP1-null fibroblasts still activate NF-κB normally 
(Conze et al., 2005; Vince et al., 2007), so the observed effects may be cell 
type specific or possibly overexpression artifacts.  XIAP may have a 
function in the bone morphogenetic protein (BMP) signaling pathway 
involved in developmental patterning.  The carboxyl-terminus of XIAP can 
bind BMP receptors, and BIR1 can bind the adaptor protein TAB1 
(Yamaguchi et al., 1999).  TAB1 in turn recruits a member of the mitogen 
activated protein kinase (MAPK) kinase kinase TAK1, which in turn 
activates NF-κB signaling (Lu et al., 2007).  The physiological significance 
of this interaction is unclear because the conclusions rely from 
overexpression experiments, and this has yet to be validated by genetic or 
other approaches. 
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1.10 IAPs in cancer and other diseases 
 
Mammalian IAPs, and XIAP in particular, can inhibit apoptosis 
triggered through diverse stimuli when overexpressed (LaCasse et al., 1998).  
Elevated IAP expression is documented in human tumors (Tamm et al., 
2000; Tamm et al., 2004), and correlates with high levels of active caspases 
(Yang et al., 2003).  There are few published correlation studies, however, 
and the prognostic significance of XIAP overexpression is unclear (Fulda, 
2007).  The tightly linked cIAP1 and cIAP2 loci are frequently amplified in 
lung cancer (Dai et al., 2003), while cIAP1 is amplified specifically in 
cervical cancer (Imoto et al., 2002) and correlates with resistance to 
radiotherapy.  cIAP1 is also amplified in human hepatocellular carcinoma 
and experimentally induced liver cancer in mice (Zender et al., 2006).  
Indeed, cIAP1 overexpression has a pathogenic role in hepatocellular 
carcinoma (Zender et al., 2006).  A chromosomal translocation common to 
extranodal marginal zone mucosa-associated lymphoid tissue (MALT) B-
cell lymphomas juxtaposes the cIAP2 BIR domains with a caspase-like gene, 
MALT1 (Baens et al., 2000; Uren et al., 2000).  The chimeric cIAP2/MALT 
protein displays enhanced NF-κB survival signaling (Zhou et al., 2005) and 
promotes tumorigenesis in a transgenic mouse model (A. Stoffel, 
unpublished data). 
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With the exception of cIAP1 in liver cancer, the associations between 
IAP overexpression and tumorigenesis remain correlative.  In spite of this, 
diverse strategies to inhibit IAPs have pro-apoptotic effects in many 
contexts.  Downregulation of XIAP through antisense or interfering RNAs, 
or therapeutic peptides derived from IAP antagonists, sensitizes tumor cells 
to apoptosis and offers some promise for future therapy (Hunter et al., 2007).  
Smac-derived peptides (Fulda et al., 2002) or small-molecules (Petersen et 
al., 2007), or XIAP antisense treatments (Cummings et al., 2006), synergize 
with apoptotic stimuli to reduce tumor xenografts in mice.  Small-molecule 
IAP antagonists have been developed by many groups, and they offer 
promising therapeutic advantages (Sun et al., 2006; Vucic and Fairbrother, 
2007).  Some of these antagonists have entered Phase I clinical trials for 
treatment in different malignancies. 
IAPs may have roles in other disease contexts as well.  Many 
neurodegenerative diseases have a strong apoptotic component, and blocking 
apoptosis could have therapeutic benefits (Mattson, 2000).  XIAP gain-of-
function models (e.g., overexpression) have been used to demonstrate 
involvement of IAPs in neurodegeneration.  Overexpression of XIAP 
protects motor neurons in an experimental model of sciatic denervation 
(Perrelet et al., 2002).  Transgenic expression of XIAP in neurons using the 
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neuron-specific enolase promoter (nse-XIAP) improves prognosis in a mouse 
model of Parkinson’s disease (Crocker et al., 2003).  Overexpression of 
XIAP also improves the survival of human pancreatic islets after 
transplantation in a mouse model of diabetes treatment (Emamaullee et al., 
2005).  Thus, IAP function may be modulated to either enhance apoptosis in 
diseases like cancer that display resistance to death, or reduce apoptosis in 
degenerative diseases.   
1.11 Concluding remarks 
 
Despite huge gains in our understanding of proteins involved in 
apoptosis, many aspects of cell death remain obscure.  This is true both for 
particular aspects of cell death (e.g., regulation of IAPs), but also in broader 
contexts.  For example, thymocytes lacking Apaf-1 (Yoshida et al., 1998) or 
caspase-9 (Hakem et al., 1998) are broadly resistance to apoptotic stimuli in 
culture, but thymus development is still largely normal.  On a mixed genetic 
background (C57BL/6 / 129), mice lacking the pro-apoptotic functions of 
cytochrome c (Hao et al., 2005), Apaf-1, caspase-9 and caspase-3 (Kuida et 
al., 1996) die with many similar brain defects that include craniofacial 
abnormalities, exencephaly, reduced apoptosis and hyperplasia.  While a 
common phenotype orders these genes in the same pathway, the penetrance 
is considerably lower on the C57BL/6 background and many of these 
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knockout mice can be viable and fertile (Leonard et al., 2002).  The identity 
of the strain-specific modifier(s) is unknown.   
These findings argue that there may be additional ways of activating 
apoptosis or other death programs apart from known pathways.  Genetic 
arguments place the activation of any such pathway downstream of 
mitochondrial control points; Apaf1-null cells expressing BH3-only proteins 
can die a caspase-independent death (Cheng et al., 2001), while BAX/BAK-
deficient cells are resistant (Wei et al., 2001).  Some insights come from C. 
elegans and its streamlined version of the apoptotic cell death pathway, 
which contains counterparts of BH3-only (egl-1, ced-13), anti-apoptotic 
BCL-2 (ced-9), Apaf-1 (ced-4) and a caspase (ced-3).  Even in this less 
complex system, there are other ways for ced-4 to kill cells independently of 
ced-3, the only caspase that appears to function in cell death (Bloss et al., 
2003; Shaham and Horvitz, 1996b).  Drosophila may prove to be a valuable 
model system too, as novel cell death regulatory mechanisms have been 
identified in specialized cells like spermatids (Arama et al., 2003).  
Redundant death pathways may substitute for apoptosis during development 
as well.  Apoptosis is the most studied cell death pathway, but it is certainly 
not the only form of programmed cell death (Abraham et al., 2007; Hetz et 
al., 2005; Overholtzer et al., 2007). 
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1.12 Prologue to the XIAP ΔRING project 
 
The study described here seeks to extend our understanding of IAP 
RING functions in mammals.  Mammalian XIAP shares several properties 
with Drosophila DIAP1, including the ability to bind to caspases, to Reaper-
family proteins, and the ability to undergo auto-ubiquitination and 
proteasome-mediated degradation in response to apoptotic stimuli (Yang et 
al., 2000).  Since these conclusions stem largely from overexpression and in 
vitro experiments, we decided to examine the role of XIAP E3-ligase 
activity for caspase regulation and apoptosis in vivo.  For this purpose, we 
used gene targeting to generate a mouse XIAP ΔRING allele which 
uncouples the caspase-binding properties of XIAP from the ubiquitin 
system.  Removing the RING stabilized XIAP in apoptotic thymocytes, 
demonstrating that XIAP E3 ubiquitin-ligase activity is a major determinant 
of XIAP protein stability in vivo.  However, loss of RING function had no 
detectable consequences for thymocyte apoptosis, virtually reproducing the 
results from a previous report for XIAP-null mice (Harlin et al., 2001).  On 
the other hand, ΔRING embryonic stem cells and fibroblasts had elevated 
caspase-3 enzyme activity and impaired ubiquitination of active caspase-3 
during apoptosis.  Furthermore, XIAP ΔRING embryonic fibroblasts were 
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strongly sensitized to TNF-α apoptosis.  Therefore, XIAP RING function 
appears to play a physiological role in certain cell types, but not others.  
Finally, deletion of the XIAP RING also significantly increased apoptosis of 
proliferating B-cells and improved the survival of mice in a mouse 
lymphoma model.  We conclude that the E3 ubiquitin-ligase activity of 
XIAP is important for the regulation of apoptosis in at least some cell types 
in vivo, and that this activity contributes to tumor suppression.  These results 
suggest that the XIAP RING may be a promising drug target for developing 









We devised a strategy to inactivate the mouse XIAP RING ubiquitin-
ligase motif by gene targeting.  The RING was deleted by replacing the start 
of the domain with stop codons, while preserving the triplicate BIR domains 
that can bind and inhibit caspases.  All stages of gene targeting were 
successful and a ΔRING colony was established.  ΔRING mice were fertile 
and born at Mendelian frequencies for gender and genotype.  Mutant mice 
were phenotypically normal and indistinguishable from wild-type mice 
when challenged in vivo by whole-body irradiation or experimental models 
of liver failure. 
2.2 INTRODUCTION 
 
Gene targeting based on homologous recombination is one of the most 
powerful tools in modern mouse genetics.  Gene targeting has opened the 
mouse genome up to manipulations that range from chromosomal 
rearrangements to precise editing of individual codons (van der Weyden et 
al., 2002).  We decided to use gene targeting to inactivate the XIAP RING 
motif for many reasons.  First, we wanted to express the ΔRING protein 
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from the endogenous promoter, because XIAP is subject to uncommonly 
complex post-transcriptional and post-translational regulation in humans and 
mice (Lewis and Holcik, 2005; Vaux and Silke, 2005).  Second, we reasoned 
this would minimize artifacts that arise when RING mutant constructs are 
overexpressed. For example, overexpression experiments in Drosophila 
would argue that RING mutations render DIAP1 a better inhibitor of 
apoptosis, while the same mutations in the endogenous gene actually cause 
lethality because of unrestrained apoptosis (L. Goyal and H. Steller, 
unpublished observations).  Third, generating a mutant animal would allow 
us to address the consequences of RING inactivation in normal mouse 
development and disease models.  Finally, it was relatively straightforward 
to create this allele because the RING is positioned at the far carboxyl 
terminus of the protein (Figure 2.1).  Thus, we could truncate the XIAP 
protein at the start of the RING domain by introducing a stop codon in place 
of the codon (C449) that marks the first amino acid of the RING.  This 
chapter describes the general strategy to generate a mouse XIAP ΔRING 
allele that lacks the RING but retains the triplicate BIR domains.  
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2.3 EXPERIMENTAL PROCEDURES 
2.3.1 Design and construction of the XIAP ΔRING targeting vector 
 
We devised a strategy to eliminate the XIAP RING (located at the far 
carboxyl terminus) using a homology-based “knock-in” replacement of the 
first two amino acids of the RING (C449 and K450) by stop codons.  The 
pK-11 plasmid (a gift from Chingwen Yang) served as the backbone for 
assembling the ΔRING targeting vector.  The targeting vector contained a 
removable positive selection cassette (PGK-neomycin phosphotransferase) 
in the sense orientation flanked by FRT sites that could be recognized and 
excised by the FLPe recombinase.  A superfluous loxP site located 
downstream of the selection cassette was removed from pK-11 before 
cloning.  A single 2.7 kB fragment containing both the final exon (encoding 
the RING) and the 2.0 kB 3’ homology arm was amplified by PCR from an 
X-chromosome bacterial artificial chromosome (RPCI 23 207E14, C57BL/6 
strain).  The first two codons of the RING were mutated to tandem stop 
codons (opal and ochre) by site-directed mutagenesis and a diagnostic SacI 
restriction site was appended immediately downstream from the stop 
codons.  This fragment was cloned into the SalI/ApaI sites located on the 3’ 
site of the FRT-Neo-FRT cassette in pK-11.  The 5’ homology arm contained 
6.0 kB of genomic DNA immediately upstream of the ΔRING mutation.  A 
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NotI restriction site (for linearizing the vector) was appended to the 5’ 
terminus during PCR, and the fragment was cloned into the SacII site on the 
5’ side of FRT-Neo-FRT.  Finally, a PGK-diphtheria toxin-A negative 
selection cassette was amplified by PCR from the vector pDTA (a gift from 
Dónal O’Carroll) and ligated in the antisense origin into the KpnI site after 
the 3’ homology arm.  The Expand High-Fidelity DNA polymerase (Roche) 
was used for PCR amplification.   
The vector was designed with the FRT-Neo-FRT cassette positioned 
in the final intron of the targeted locus, adjacent to the sixth exon encoding 
the RING.  The final targeted locus (following excision of FRT-Neo-FRT by 
FLPe) would thus contain only the introduced stop codons (and diagnostic 
restriction site) in the final exon, and one residual intronic FRT site flanked 
by the SacII and SalI restriction sites introduced for cloning purposes.  We 
presumed that this short, 55-nucleotide piece of DNA remaining in the 
intron would not affect the synthesis or splicing of the ΔRING mRNA.  PCR 
genotyping primers that flank the insertion site of the residual DNA were 
chosen to distinguish WT from ΔRING alleles based on the larger size of the 
PCR product from the ΔRING locus (Forward primer sequence: 5’-TAA 
AGC CTT TAC CTT CTT CTC TAT TTC C-3’; reverse primer sequence: 
5’-TGG GAC AGG TAG GAT TTA GTG CTT CG-3’; annealing 
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temperature of 55 C).  The targeting vector was sequenced to confirm that 
the vector was assembled correctly and that no other mutations were 
introduced during PCR amplification of the BAC DNA template. 
2.3.2 Gene targeting, generation of chimeric mice, and establishment of a 
ΔRING colony 
 
100 µg of plasmid DNA were digested for 2 hours with NotI to 
linearize the vector, and then extracted by ethanol and resuspended in water.  
Gene targeting in mouse embryonic stem cells (E14 line, 129/Ola strain) was 
conducted by the Rockefeller University Gene Targeting Resource Center 
according to standard techniques (Nagy, 2003).  Briefly, ES cells were 
electroporated with the linearized DNA, plated on a feeder layer of 
mitotically arrested neomycin-resistant fibroblasts, and then cultured in 200 
µg/mL G418 to select for neomycin-resistant colonies.  Individual 
neomycin-resistant, replica-plated colonies were selected and screened for 
homologous targeting of the XIAP locus by Southern blotting of SacI 
digested genomic DNA.  For this purpose, we used a 312-bp probe created 
by PCR from outside the 3’ homology arm (Forward primer sequence: 5’-
TCG GAA GGT CAC AGA ATA ACC G; reverse primer sequence: 5’-
CCC AGC GAA TCA CAT TGT AGT CAC; PCR annealing and Southern 
hybridization temperature of 55 C).  Independently targeted clones were 
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expanded on feeder layers and karyotyped.  Three ES clones with normal 
diploid genomes were injected into C57BL/6 blastocysts and implanted into 
pseudopregnant females by the Transgenic Services facility at Rockefeller 
University, using standard techniques (Nagy, 2003).   
Strongly chimeric male mice (as gauged by the highest penetrance of 
the chinchilla coat color modifier gene from the 129/Ola background) were 
selected for backcrosses to transgenic C57BL/6 “FLPeR” females, 
expressing FLPe from the constitutive ROSA26 locus (Farley et al., 2000), to 
remove the neomycin cassette in vivo.  FLPeR mice were a gift from Dónal 
O’Carroll and genotyped by PCR (Forward primer sequence: 5’-CAC TGA 
TAT TGT AAG TAG TTT GC; reverse primer sequence: 5’ CTA GTG 
CGA AGT AGT GAT CAG G) according to the published protocol (Farley 
et al., 2000). 
The presence of any agouti pups in the litters indicated germline 
transmission of the mutant allele; this was confirmed by Southern blotting of 
tail biopsy DNA.  Excision of the Neo cassette in progeny was assessed by 
Southern blotting of ApaLI digested genomic DNA from tail biopsies, using 
the same probe described above, and also by PCR using the genotyping 
primers.  Animals positive for the mutant allele and Neo excision, and 
negative for the FLPe transgene, were selected to establish the colony.  
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Initial experiments were conducted using mice on a mixed 129/Ola / 
C57BL/6 genetic background.  A congenic strain was established on the 
C57BL/6 background by serial backcrossing for over ten generations.  
Animals were housed in a specific pathogen free environment with 
unlimited access to food and water in the LARC vivarium at the Rockefeller 
University.  The institutional animal care and use committee approved all 
experiments under animal protocols 04-058 and 07-059. 
2.3.3 Aging and irradiation experiments 
 
Aging cohorts of male mice on a mixed 129/Ola / C57BL/6 
background (WT, n=14; ΔRING, n=19) were set aside and monitored 
periodically for the incidence of disease or death.  Another cohort of mice 
derived after backcrossing to the C57BL/6 background for at least 5 
generations (n=13 for both genotypes) was selected for an in vivo irradiation 
experiment.  Mice were administered antibiotics (30 mg/L neomycin, 30 
mg/L kanamycin, 10 mg/L gentamicin) in their drinking water for two days 
prior to a single 7-Gy dose of ionizing radiation from the LARC X-ray 
source (1.8 Gy/min).  Irradiated mice were given continued access to the 
antibiotic drinking water and monitored for survival over time.  Kaplan-
Meier survival curves were constructed and analyzed with a log-rank 
statistical test in the Prism 4.0 software package (GraphPad Software, Inc.). 
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We also submitted pairs of littermate mice that ranged in age from 50 
to 150 days for complete histopathological analysis by the Laboratory of 
Comparative Pathology at the Memorial Sloan-Kettering Cancer Institute.  
The pathologists were not informed of the genotypes of the mice or the 
nature of the project to ensure an unbiased examination. 
2.3.4 TNF-α and Fas-dependent liver apoptosis 
 
Agonstic anti-Fas antibody (10 µg Jo-2 antibody [BD Biosciences] in 
200 µL sterile phosphate-buffered saline [PBS]), or 300 ng TNF-α 
(Peprotech) and 20 mg D-galactosamine (GalN; Sigma) in 200 µL PBS, was 
administered to age-matched mice by lateral tail vein injection.  Mice were 
sacrificed by cervical dislocation, at a time (Fas, 4 hours; TNF-α/GalN: 6 
hours) when mice were moribund but still alive.  Livers were surgically 
removed and snap-frozen in liquid nitrogen.  Livers were homogenized in 
lysis buffer (10 mM Tris [pH 7.5], 100 mM NaCl, 1mM EDTA, 0.01% 
Triton X-100) using a Polytron (Kinematica) and clarified by centrifugation 
at 14,000 RPM for 10 minutes at 4 C, before determining total protein 
concentration using the Bradford reagent (Bio-Rad).  150 µg of total protein 
from each sample were assayed for caspase-3 activity in bulk by measuring 
the linear rate of cleavage of a fluorescent Z-DEVD-R110 substrate using 
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the EnzChek Caspase-3 Assay Kit #2 (Invitrogen) and a SpectraMax M2 
multiwell plate reader (Molecular Devices).  
2.3.5 Statistical treatments 
 
All bar graphs values are displayed as means with standard error unless 
noted otherwise. 
2.4 RESULTS  
2.4.1 Generation of ΔRING mice by gene targeting and blastocyst injection 
 
We used homology-based gene targeting in mouse embryonic stem 
(ES) cells to create a XIAP ΔRING mutant allele by replacing the first two 
amino acids (C449 and K450) of the RING domain with stop codons (Figure 
2.1).  This mutation was designed to truncate the RING and the thirteen 
amino acid sequence between the end of the RING and the carboxyl 
terminus, while leaving intact the triplicate BIR domains in the amino- 
terminal half of XIAP.  After targeting the XIAP locus in the E14 embryonic 
stem (ES) cell line with a conventional replacement strategy, 6 of 96 
neomycin-resistant ES colonies showed restriction fragment length 
polymorphisms consistent with precise homologous targeting; an example 
Southern blot autoradiograph is shown in Figure 2.2A.  Correct insertion of 
the stop codons was confirmed by directly sequencing genomic DNA from  
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Figure 2.1 Gene targeting strategy. WT XIAP protein structure is shown at 
top. Second line: genomic organization of the XIAP locus, indicating WT 
stop codon and the location of the Southern probe. Third line: targeting 
vector, indicating ΔRING stop and FRT sites (open triangles); DTA denotes 
negative selection cassette.  Third line: Targeted ΔRING (Neo) locus.  Fourth 
line: Final ΔRING (ΔNeo) locus after FLPe excision of Neo; grey 
arrowheads indicate location of genotyping primers that flank residual FRT 
site.  ΔRING XIAP protein structure is shown at bottom. 
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Figure 2.2 Gene targeting results. (A) Southern blot of SacI-digested DNA 
from Neo-resistant ES colonies using the probe in Figure 2.1; numbers 
indicate individual colonies (B) Southern blot of SacI-digested tail biopsy 
DNA. (C) Southern blot of ApaLI-digested DNA from mice crossed to 
FLPeR deletor strain. (D) PCR genotyping of mice. (E) DNA sequencing 
chromatograph from Exon 6 in WT and ΔRING alleles in ES cells; asterisks 
indicate stop codons. (F) DNA sequence of residual intronic DNA in ΔRING 
allele. 
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targeted clones (Figure 2.2E).  We decided to remove the Neo cassette in 
vivo to minimize the time ES cells spent in culture; therefore, the ES cells 
used for blastocyst injection had the genomic organization shown in the 
ΔRING (Neo) line in the targeting schematic (Figure 2.1). 
Two of three independently targeted clones with normal diploid 
karyotypes (#49, #129) yielded mice with strongly chimeric coat colors after 
blastocyst injection and implantation into foster mothers from the C57BL/6 
inbred strain; a third clone (#165) produced no chimeras.  Chimeric males 
from both founder lines (line 49: 3 of 7 chimeras; line 129: 5 of 11 chimeras) 
transmitted the mutant allele through the germline when backcrossed to 
C57BL/6 “FLPeR” females expressing the FLPe recombinase.  This was 
evident by the presence of pups with the dominant agouti coat color and 
verified by Southern blotting of SacI digested DNA tail biopsies (Figure 
2.2B).  Excision of the Neo cassette was confirmed in these animals by 
Southern blotting of ApaLI digested DNA (Figure 2.2C).  This was 
corroborated by PCR genotyping across the residual FRT site in a Neo-
deleted locus (Figure 2.2D) and direct DNA sequencing (Figure 2.2F).  
Collectively, the genotyping results confirmed that we had derived mice 
with the final, correctly targeted XIAP ΔRING (ΔNeo) locus.  Mice derived 
from targeted clone #129 were chosen arbitrarily to found the colony. 
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2.4.2 Analysis of an aging cohort of mice 
 
ΔRING mice were fertile and born at expected Mendelian ratios for 
gender and genotype (Table 1).  We submitted age-matched wild-type and 






Genotype Number with 
genotype 
Predicted 
Female 42 40 WT/WT 19 20 
   WT/ΔRING 23 20 
Male 38 40 WT/- 18 20 
   ΔRING/- 20 20 
Table 1 Distributions of gender and genotype in ΔRING litters. Tally of 
the number of mice of different gender and genotype in 11 litters (n=80 
mice).  Parental crosses: WT/- male x WT/ΔRING female. 
 
comprehensive, unbiased histopathological examinations by an outside 
laboratory.  ΔRING mice were indistinguishable from WT littermates at 
different ages when examined in a blind manner.  Moreover, ΔRING mice 
have shown no overt susceptibility to disease or premature death in our 
pathogen free mouse colony after more than 24 months of age (Figure 2.3).  
These observations are consistent with those of XIAP-null mice, which 
develop mostly normally (Harlin et al., 2001; Olayioye et al., 2005).  These 
results argue that the RING domain was dispensable for fertility and normal 
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development on this mixed genetic background.  We derived a congenic 
mutant strain by repeatedly backcrossing (n>10 generations) to the C57BL/6 
inbred strain; these mice are also fertile and phenotypically normal.  
2.4.3 Whole-body irradiation 
 
Treatment of mice with a single whole-body dose of ionizing radiation 
leads to mortality over the course of roughly two weeks, probably in 
response to p53-dependent apoptosis of all hematopoietic precursors in the 
bone marrow, in addition to other radiosensitive renewable tissues 
(Westphal et al., 1998).  We irradiated a cohort of WT and mutant mice to 
determine if loss of the RING domain influenced survival in a paradigm of 
DNA damage induced apoptosis.  The survival curves for mice of both 
genotypes were comparable following a single 7-Gy dose of X-irradiation 
(Figure 2.3).  The median survival time for WT mice was 12 days and 11 
days for ΔRING mice.  Since survival kinetics were unaltered in mutant 
mice, the loss of XIAP E3 ubiquitin-ligase activity did not affect death that 
occurs following DNA damage caused by X-irradiation in vivo. 
2.4.4 In vivo hepatocyte apoptosis 
 
Antibodies against the Fas death receptor function as agonists that trigger 




Figure 2.3 Aging and Whole-Body Irradiation Survival Curves. (A) 
Kaplan-Meier survival curve of an aging cohort of mice; p=0.25. (B) 
Kaplan-Meier survival curve of mice following 7-Gy of whole-body 
irradiation; p=0.44.  Log-rank test was used for significance. 
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(Ogasawara et al., 1993).  Likewise, administration of the TNF-α cytokine in 
combination with an inhibitor of transcription (e.g., D-galactosamine, 
“GalN”) provokes acute hepatitis accompanied by severe apoptosis, 
ultimately leading to the death of the animal within hours (Leist et al., 1994).  
Both are models for death receptor apoptosis in vivo.  Although the 
downstream effector pathways are distinct for Fas- and TNF-α-dependent 
apoptosis, activation of either pathway leads to caspase-3 activation.  We 
administered either treatment to WT and ΔRING mice to see if the RING 
domain influenced these in vivo paradigms of hepatocyte apoptosis.  
Animals were sacrificed 4 hours after Fas or 6 hours after TNF-α/GalN 
treatment and assayed for caspase-3-like activity in the liver, as an endpoint 
readout for hepatocyte apoptosis.  WT and ΔRING mice showed comparable 
caspase-3 activity in response to these treatments.  WT mice became 
moribund roughly at the same time as ΔRING mice.  Although we did not 
perform any TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP 
nick end labelling) to corroborate the caspase assay, these experiments show 
that deletion of the RING domain did not affect caspase activity in vivo in 




Figure 2.4 Liver apoptosis. Caspase-3-like activity measured in liver 





The results shown here imply that XIAP ubiquitin-ligase function was 
dispensable for development and survival on mixed and congenic 
backgrounds.  The XIAP ΔRING mouse is similar in these respects to the 
two XIAP-null mice that have been engineered, neither of which displays 
any severe developmental defects (Harlin et al., 2001; Olayioye et al., 2005).  
To date, the only phenotype described at the level of the whole animal is 
delayed lobuloalveolar development in the mammary gland, but XIAP-null 
dams are still able to nurse litters (Olayioye et al., 2005).  The lack of an 
apoptosis phenotype in the liver following Fas or TNF-α/GalN 
administration contrasts with the results presented in Chapter 5, where a 
sensitivity to TNF-α-dependent apoptosis is described in embryonic 
fibroblasts. 
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3 APOPTOSIS IN ΔRING THYMOCYTES AND OTHER 
PRIMARY HEMATOPOETIC CELLS  
3.1 SUMMARY 
 
The evidence that RING domains promote IAP turnover was first 
uncovered by studying mouse thymocytes undergoing apoptosis.  We used 
ΔRING thymocytes to test the hypothesis that RING-mediated turnover can 
facilitate cell death.  The RING was the principal determinant of XIAP 
stability during thymocyte apoptosis.  This is consistent with the notion that 
the XIAP RING functions as an E3 ubiquitin-ligase to promote XIAP 
turnover.  Enhancing XIAP stability by removing the RING did not affect 
caspase activation or activity, and ΔRING thymocytes underwent normal 
apoptosis.  T- and B-cell development in the thymus and bone marrow, 
respectively, was unaltered in ΔRING mice.  Collectively, these data imply 
that the RING was important for XIAP stability, but increasing the 
abundance of XIAP by deleting the RING did not impede apoptosis or alter 
hematopoietic development.  
3.2 INTRODUCTION 
3.2.1 General comment on apoptosis in immunity 
 
Cell death pathways regulate the development and homeostasis of the 
immune system.  Virtually every step in B- and T-cell development is 
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governed by checkpoints that can activate apoptosis when developmental 
programs go awry, thereby eliminating non-functional or auto-reactive 
lymphocytes.  Lymphocyte survival depends on the proper integration of 
cell-autonomous and external signals.  Lymphocyte apoptosis involves both 
mitochondrial- and receptor-dependent death pathways (Rathmell and 
Thompson, 2002).  These pathways function in development and maturation 
of lymphocytes, and to attenuate the immune response after an infection 
(Opferman, 2007).  Proper regulation of apoptosis in the lymphoid system is 
important for preventing autoimmunity and cancer as well (Krammer, 2000). 
3.2.2 Apoptosis in developing lymphocytes 
 
T-cell development is regulated by control checkpoints that can 
trigger cell death to maintain the quality of the T-cell pool.   T-cell 
progenitors originate in the bone marrow but hone to the thymus for 
development and maturation (Jotereau et al., 1987) (Carlyle and Zuniga-
Pflucker, 1998).  Stringent quality control results in the death of 
approximately 97% of developing T-cells in the thymus without any evident 
inflammation (Shortman et al., 1990).  Indeed, a high index of apoptosis is 
seen in situ, while apoptotic thymocytes are cleared very rapidly (Surh and 
Sprent, 1994).  Apoptosis is evident at the earliest stages of thymocyte 
development as T-cell precursors compete for the survival factor interleukin-
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7 (Baird et al., 1999): cells deprived of interleukin-7 undergo apoptosis that 
depends on the BH3-only gene BIM (Bouillet et al., 1999) and is blocked by 
BCL-2 overexpression (von Freeden-Jeffry et al., 1997).  
 One of the hallmark events of T-cell development is the somatic 
rearrangement of T-cell receptor (TCR) genes to create specificities for 
diverse antigens.  Thymocytes that fail to arrange a functional TCR undergo 
“death by neglect”, although the molecular mechanism remains unclear 
(Ashwell et al., 2000).  A prevailing hypothesis holds that signaling through 
the TCR, possibly transduced by Ras through the ERK (extracellular signal-
related kinase) effector pathway (Alberola-Ila et al., 1996), rescues 
thymocytes from apoptosis that would otherwise occur by default in 
response to ambient glucocorticoids in the thymic microenvironment 
(Zacharchuk et al., 1990).  Thymocytes expressing a functional TCR escape 
death by neglect, upregulate the CD4 and CD8 surface antigens, and become 
subject to positive and negative selection.   
The TCR recognizes antigens presented by major histocompatibility 
complexes (MHC) on dendritic cells and macrophages, and this interaction 
is necessary for T-cell function.  A TCR that recognizes a MHC with the 
proper avidity initiates Ras survival signalling in the process known as 
positive selection (Yang and Ashwell, 1999).  Cells that fail positive 
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selection die in the thymus (Huesmann et al., 1991) (Merkenschlager et al., 
1997).  Negative selection eliminates T-cells that bind a cognate MHC too 
tightly and helps ensure a pool of self-tolerant T-cells (Kappler et al., 1987).  
Thymocytes that undergo positive selection and survive negative selection 
proceed to downregulate either CD4 or CD8 to become cytotoxic or helper 
T-cells, respectively, and migrate to the periphery.   
The mitochondrial pathway of apoptosis has a prominent role in 
thymocyte apoptosis.  Negative selection depends on the BH3-only protein 
BIM, as BIM-null mice fail to eliminate many self-reactive thymocytes 
(Bouillet et al., 2002) and develop autoimmunity (Bouillet et al., 1999). 
BAX and BAK together control most of the death that occurs in T-cell 
development, and mice genetically deficient for both genes accumulate T-
lymphocytes across many developmental stages (Lindsten et al., 2000).  
BCL-2 overexpression inhibits the death of double-positive thymocytes that 
do not undergo positive selection (Strasser et al., 1994), but not death by 
neglect that occurs in the absence of a functional TCR (Maraskovsky et al., 
1997).  BCL-2 overexpressing thymocytes remain self-tolerant, so other 
mechanisms are likely in place to ensure deletion of autoreactive thymocytes 
(Sentman et al., 1991). 
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Analogous apoptotic checkpoints function during B-cell development, 
which occurs primarily in the bone marrow.  B-cells also depend on cytokine 
signaling for survival and to avoid death by neglect (Baird et al., 1999).  
Developing B-cells that receive sufficient interleukin-7 upregulate the 
antiapoptotic BCL-2 family member, MCL1, and this is believed to impart 
resistance to apoptosis at this developmental stage (Opferman et al., 2003).  
Apoptosis functions in eliminating B-cells that do not generate a functional, 
self-tolerant B-cell receptor during development in the bone marrow 
(Melchers et al., 2000).  As with T-cells, the death of autoreactive B-cells 
depends largely on BIM (Bouillet et al., 1999), and almost entirely on BAX 
and BAK (Takeuchi et al., 2005).  BCL-2 overexpression prevents many of 
these deaths (Hartley et al., 1993). 
3.2.3 Apoptosis in peripheral T- and B-cells 
 
  The numbers of peripheral lymphocytes are tightly controlled, in large 
part by apoptosis that balances out proliferation in cells involved in antigen-
dependent immune responses.  Death receptor signaling appears to have a 
more prominent role in maintaining homeostasis in the periphery than it does 
during lymphocyte development (Rathmell and Thompson, 2002).  For 
example, Fas death receptor signaling instructs the death of clonal 
populations of activated T-cells in a waning immune response (Krammer, 
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2000).  Mice and humans with deficiencies in the Fas receptor pathway 
develop autoimmunity and accumulate peripheral self-reactive lymphocytes.  
Mice that lack both Fas and BIM show the most striking accumulation of 
peripheral T-cells (Hughes et al., 2008), which points to the combined 
effects of these pathways in regulating immune homeostasis.  Antibody-
producing plasma B-cells also die during a waning immune response.  The 
molecular underpinnings of death in these cells probably involve both Fas 
and BIM as well (Hutcheson et al., 2008; Rothstein et al., 1995). 
3.2.4 Roles of IAPs in thymocyte apoptosis 
 
The first functions described for the XIAP and cIAP1 RING domains 
were the capacity to serve as E3 ubiquitin ligases that promote 
autoubiquitination and IAP degradation during mouse thymocyte apoptosis 
(Yang et al., 2000).  Additionally, a ΔRING XIAP mutant protein is resistant 
to ubiquitination, stably expressed, and imparts resistance to apoptosis when 
expressed in a mouse T-cell hybridoma (Yang et al., 2000).   The 
observation that efficient thymocyte apoptosis requires the proteasome 
(Grimm et al., 1996) led to a hypothesis that IAP RINGs may act 
proapoptotically in these cells by engaging the ubiquitin system to relieve a 
break on cell death pathways by degrading IAPs (Yang and Li, 2000).  
Studies on DIAP1 in Drosophila provide a precedent for a pro-apoptotic 
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RING function during apoptosis.  Expression of the DIAP1 antagonist 
Reaper depletes DIAP1 through RING-dependent autoubiquitination, 
leading to apoptosis in the wing imaginal disc (Ryoo et al., 2002).  
Furthermore, Ubcd1, the cognate E2 ubiquitin-conjugating enzyme for 
DIAP1, is required for Reaper-dependent apoptosis (Ryoo et al., 2002).   
Thymocytes from mice deficient in XIAP, cIAP1 or cIAP2 are not 
strongly sensitized to apoptotic stimuli in vivo or under culture conditions, 
although there are subtle reductions in thymus size in cIAP1-null mice 
(Conte et al., 2006; Conze et al., 2005; Harlin et al., 2001).  In contrast, the 
total thymocyte count increases and T-cells accumulate in the spleen when 
human XIAP is expressed transgenically in mice by the thymocyte-specific 
lck promoter (Conte et al., 2001).  Thymocytes from the lck-XIAP transgenic 
mouse are also resistant to diverse apoptotic stimuli in vivo and in culture, 
including an experimental mimic of negative selection and glucocorticoid 
treatment.  The CD4:CD8 (single-positive) T-cell ratio is also inverted in the 
thymus; similar observations are seen in lck-Bcl2 mice (Sentman et al., 
1991).  The authors attribute the resistance to apoptosis to the increased 
stability of human XIAP overexpressed from the mouse lck promoter (Conte 
et al., 2001).  Therefore, data from transgenic mice suggest that the 
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persistence of stabilized XIAP during thymocyte apoptosis may inhibit 
death. 
In this chapter, we describe experiments designed to test the 
hypothesis that the XIAP RING can act pro-apoptotically in thymocytes by 
serving as a ubiquitin-ligase to direct XIAP downregulation.  We reasoned 
that genetic deletion of the RING would prevent autoubiquitination and 
ubiquitination in trans by other IAPs (Silke et al., 2005), and that stabilized 
XIAP may impair lymphocyte cell death by continuing to inhibit caspases. 
3.3 EXPERIMENTAL PROCEDURES 
3.3.1 Isolation and culture of primary lymphocytes 
 
Adolescent (4-6 week old) littermate mice were selected for 
thymocyte experiments because the thymus undergoes involution and 
decreases in size after adolescence.  Animals were sacrificed using CO2 gas 
and thymic lobes were dissected under sterile conditions in 2% (v/v) fetal 
bovine serum (FBS; Hyclone) in PBS (pH 7.4).  Single cell thymocyte 
suspensions were prepared by mincing thymi in FBS/PBS through a 40 µm 
nylon mesh cell strainer.  Cells were collected by centrifugation (3 minutes, 
1000 RPM, 4 C), then treated with erythrocyte lysis buffer (9 volumes of 
150 mM NH4Cl, 1 volume of 130 mM Tris-Cl [pH 7.65]) for 3 minutes at 
room temperature.  Thymocytes were collected again by centrifugation and 
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resuspended in thymocyte medium (RPMI medium supplemented with 10% 
FBS, 100 U/mL penicillin [Gibco], 100 µg streptomycin [Gibco], and 2 mM 
L-Glutamine[Gibco]) at a density of 5 x 106 cells/mL, generally in T25 
flasks or 6-well plates. 
 B-cells were purified from spleens by first creating single-cell 
splenocyte preparations and lysing erythrocytes as described above.  Cells 
were resuspended at a density of 1 x 107 cells per 40 µL FBS/PBS and 
incubated for 10 minutes at 4 C with a biotin-conjugated antibody cocktail 
that labelled the predominant non-B-cell populations in the spleen 
(Miltentyi).  Non-B-cells were labelled secondarily with anti-biotin magnetic 
beads and depleted by flowing samples through a magnetic column.  Isolated 
splenic B-cell populations in the flow-through were used for downstream 
assays; purity was verified by fluorescent immunostaining and flow 
cytometry as described below.  B-cells were cultured in B-cell medium 
(45% Iscove's MEM, 45% DMEM, 10% FBS, 100 U/ml penicillin, 100 g/ml 
streptomycin, 4 mM l-glutamine, and 25 µM β-mercaptoethanol [Sigma]) at 





3.3.2 Apoptosis assays 
 
Thymocytes were treated in culture with 10 µM etoposide (Sigma) or 
1 µM dexamethasone (Sigma) to induce apoptosis, or left untreated in 
thymocyte medium as a control for spontaneous death under cell culture 
conditions.  Thymocytes were also treated with 100 ng/mL TNF-α with and 
without 10 µM cycloheximide (Sigma).  B-cells were treated with 10 µM 
etoposide or left untreated in B-cell medium.  For some experiments, the 
peptide aldehyde proteasome inhibitor MG-132 (Calbiochem) or the pan-
caspase inhibitor zVAD-fmk (Alexis) was added at a final concentration of 
20 µM. 
3.3.3 FLICA labeling of the caspase-3 active site 
 
To analyze of caspase-3 activation, thymocytes were treated with 
dexamethasone or left untreated in 96-well plates for 5 or 7 hours, then 
incubated with the FAM-DEVD-FMK FLICA (caspase-3, principally) or 
FAM-LEHD-FMK (caspase-9, but crossreacts with other caspases) reagent 
(Immunochemistry Technologies; diluted from 150X stock) for an additional 
hour.  Unbound FLICA reagent was removed by pelleting cells through 
centrifugation in the 96-well plate, decanting the medium, and washing 
twice with the 1X wash buffer supplied in the FLICA kit.  Cells were 
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resuspended in 100 µL wash buffer supplemented with 40 ng/mL propidium 
iodide (PI).  The number of apoptotic cells was determined with a 
FACScalibur flow cytometer (BD Biosciences) by gating PI-negative, 
carboxyfluorescein-positive cells among at least 4000 total cells. 
3.3.4 Annexin-V/propidium iodide and TUNEL apoptosis assays 
 
Thymocytes were treated with dexamethasone or left untreated in 
thymocyte medium in 96-well plate for 8 hours, then collected by 
centrifuging the entire plate and decanting culture medium.  For TUNEL, 
cells were washed twice in 0.5% bovine serum albumin (BSA; Sigma) in 
PBS (pH 7.4) and fixed in 2% paraformaldehyde for 10 minutes at 37 C.  
Cells were washed twice in BSA/PBS and permeabilized in 70% ethanol for 
30 minutes at -20 C.  Cells were washed twice in BSA/PBS before 
performing the TUNEL reaction for 60 minutes at 37 C according to the 
manufacturer’s directions (MBL International).  Cells were washed again 
before flow cytometry.  The percentage of apoptotic cells was determined by 
counting the number of fluorescein-positive cells among 4000 cells per 
sample.  For annexin-V/propidium iodide labelling, cells were collected and 
labelled in flow cytometry tubes (100 µL) with 4 µL propidium iodide (50 
µg/mL stock) and 2 µL annexin-V-FITC (BD Biosciences) for 10 minutes at 
room temperature before flow cytometry. 
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3.3.5 Caspase-3-like (DEVDase) enzyme activity assay 
 
3x107 thymocytes were treated in T25 flasks with etoposide or 
dexamethasone, or left untreated, for 8 hours before collecting cells by 
centrifugation.  Cell pellets were first frozen at -80 C and then lysed in 
DEVDase assay lysis buffer (described in Chapter 2) for 20 minutes on ice.  
Lysates were clarified by centrifuging tubes for 5 minutes at 5000 RPM at 
room temperature, and the protein concentrations were determined using the 
Bradford reagent (Bio-Rad).  Bulk caspase-3-like activity was determined 
from 50 µg total protein as described in Chapter 2. 
3.3.6 Immunoblotting 
 
Cells were homogenized in lysis buffer (20 mM Tris [pH 7.5], 150 
mM NaCl, 1mM EDTA, 1 mM EGTA, 1% Triton X-100) supplemented 
with protease inhibitors (1 mM PMSF, 2 µg/mL leupeptin, 100 nM 
benzamidine, 1 µM pepstatin A).  Lysates were incubated on ice for 30 
minutes and clarified by centrifugation (14,000 RPM, 10 minutes, 4 C) 
before normalizing protein concentrations using the Bradford assay.  Protein 
samples were resolved on SDS-PAGE Ready Gels (Bio-Rad) and 
electroblotted on Immobilon-P membranes (Millipore).  Membranes were 
blocked for one hour at room temperature in blocking buffer (5% [w/v] 
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nonfat milk in 0.5% [v/v] Tween 20/PBS) and incubated overnight at 4 C 
with antibodies dissolved in blocking buffer.  Membranes were washed with 
0.5% Tween 20/PBS wash solution, incubated for 30 minutes at room 
temperature with appropriate secondary antibodies (conjugated to 
horseradish peroxidase and diluted in blocking buffer), before washing 
again.  Signals were detected with the West Femto chemiluminescent kit 
(Pierce Biotechnology) on Bio-Max film (Kodak). 
3.3.7 Analyzing the cellular compositions of the thymus, spleen and bone 
marrow 
 
The distribution of major thymocyte subpopulations was determined 
in single-cell suspensions by flow cytometry, using fluorescently labelled 
antibodies against surface markers CD4 and CD8.  Total cell counts in the 
thymus were calculated using a hemocytometer.  The spleen was analyzed in 
an analogous manner by creating single-cell splenocyte suspensions and 
lysing erythrocytes, then staining with antibodies directly conjugated to 
fluorophores.  The composition of the bone marrow was determined by 
flushing the marrow from femurs and tibias, treating with erythrocyte lysis 
buffer and staining with antibodies.  Cells were labelled with antibodies (BD 
Biosciences) for 20 minutes on ice; dilutions were CD19-FITC (1:100); 
CD90-PE (1:100); B220-APC (1:50); IgD-FITC (1:100); IgM-PE (1:200); 
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CD43-FITC (1:100); CD8-FITC (1:100); CD4-PE (1:200); cKIT-FITC 
(1:100); Sca1-PE (1:200). 
3.4 RESULTS 
3.4.1 RING ubiquitin-ligase activity was the primary determinant of XIAP 
stability during thymocyte apoptosis  
 
If RING-mediated downregulation of IAPs is necessary for efficient 
apoptosis, we reasoned that genetic deletion of the XIAP RING would allow 
us to determine if IAP RINGs can act pro-apoptotically.  Indeed, ΔRING 
XIAP was more stable than full-length XIAP in cultured thymocytes dying 
in response to the glucocorticoid dexamethasone, a physiological trigger of 
cell death, or the topoisomerase inhibitor etoposide, which elicits DNA 
breaks (Figure 3.1A).  The basal expression of ΔRING XIAP was greater, 
and it was cleaved over time during apoptosis.  Deletion of the RING did not 
alter the basal expression or downregulation of cIAP1 during apoptosis 
(Figure 3.1A).  XIAP and cIAP1 can bind each other in a RING dependent 
manner (Silke et al., 2005), and our genetic evidence showed that the XIAP 
RING did not influence the abundance of cIAP1 in thymocytes.  This result  
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Figure 3.1 The RING was the primary determinant of XIAP stability in 
thymocytes and splenocytes. (A) Immunoblotting of WT and ΔRING 
thymocytes treated with etoposide, dexamethasone or left untreated for 
indicated times. (B) Immunoblotting of thymocytes treated for 8 hours with 
etoposide or dexamethasone, with or without the proteasome inhibitor MG-
132 or the pan-caspase inhibitor zVAD-fmk. (C) Splenocytes were treated 
with etoposide for 8 hours or left untreated before immunoblotting. n.s. 
indicates a non-specific band detected by the XIAP antibody in B-cells, used 
as a loading control. 
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is consistent with the finding that cIAP1 expression is unchanged in XIAP-
null thymocytes (Conze et al., 2005).  It is unclear if XIAP ubiquitinates its 
binding partner Smac/DIABLO (Creagh et al., 2004; MacFarlane et al., 
2002). Smac/DIABLO expression was unchanged in non-apoptotic ΔRING 
thymocytes and it was still downregulated during apoptosis (Figure 3.1A).  
Although XIAP can ubiquitinate active caspase-3 in certain situations and 
this can lead to decreased subunit abundance (Suzuki et al., 2001), we found 
caspase-3 was activated with comparable kinetics and to similar extents 
(Figure 3.1A).  
 Consistent with prior reports (Yang et al., 2000), a peptide aldehyde 
inhibitor of the proteasome, MG-132, blocked the decrease of full-length 
XIAP during apoptosis while the pan-caspase inhibitor zVAD-fmk had 
negligible effects (Figure 3.1B).  In striking contrast, ΔRING XIAP 
expression was far more sensitive to caspase inhibition, as zVAD-fmk fully 
prevented the decrease in protein levels and abolished the cleavage product, 
while MG-132 had a much lesser effect by comparison (Figure 3.1B).  This 
result supports the hypothesis that the RING engages the ubiquitin system to 
promote XIAP turnover in apoptotic thymocytes.  cIAP1 and 
Smac/DIABLO protein levels were not affected by the RING deletion, and 
they remained labile during apoptosis (Figure 3.1A).  This leaves open the 
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possibility that other IAP E3-ligases may be responsible for targeting these 
proteins for degradation. 
We also isolated splenocytes (a heterogeneous population of 
approximately 50% B-cells and 30% T-cells; see Figure 3.6) and cultured 
them with etoposide to induce apoptosis.  We also observed enhanced 
stability of ΔRING XIAP during apoptosis in splenocytes (Figure 3.1C).  
PARP (poly ADP-ribose polymerase) cleavage was used as a readout for 
caspase-3 activity; the native 100 kDa form of PARP was cleaved similarly 
in WT and ΔRING cells as splenocytes died spontaneously in the culture 
medium and in response to etoposide (Figure 3.1C). 
3.4.2 Genetic deletion of the XIAP RING did not influence thymocyte 
apoptosis 
 
We next asked if stabilizing XIAP had any impact on thymocyte cell death, 
since ΔRING XIAP efficiently blocks glucocorticoid-induced apoptosis 
when expressed ectopically in a T-cell hybridoma (Yang et al., 2000).  We 
counted the numbers of cells harboring active caspases using fluorescent 
inhibitor of caspases (FLICA) reagents that covalently label caspase active 
site cysteines with fluorophores.  We used a FAM-DEVD-FMK reagent to 
label effector caspases (principally caspase-3, but also -6 and -7 to lesser 
extents) or a FAM-LEHD-FMK reagent to label caspase-9 (though it cross- 
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Figure 3.2 FLICA labeling of thymocyte active caspases. Histogram plots 
of fluorescence intensity after caspase active sites were labeled with FLICA 
affinity tags in thymocytes treated as indicated. 
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reacts with other caspases).  We did not see any differences in caspase 
induction using these reagents when thymocytes were induced to die with 
dexamethasone or left untreated for different times (Figure 3.2).  Moreover, 
caspase-3 enzyme activity was comparable in both untreated and apoptotic 
WT and ΔRING  (Figure 3.3A).  These results show that deleting the XIAP 
RING did not affect caspase activation or activity in thymocytes. 
We characterized apoptosis using annexin-V/propidium iodide (“PI”) 
labelling as a readout for membrane integrity, and TUNEL as a readout for 
cleavage of genomic DNA largely dependent on and downstream of 
caspase-3 (Woo et al., 1998).  Neither annexin-V/PI (Figure 3.3B) nor 
TUNEL (Figure 3.3C) revealed any differences in etoposide- or 
dexamethasone-induced apoptosis in ΔRING thymocytes.  This finding is in 
line with our results showing unaltered caspase activation and activity in 
mutant cells.  We also cultured thymocytes for 24 hours to characterize the 
amount of spontaneous death ex vivo.  AnnexinV/PI staining showed no 
difference in apoptosis in this situation, and FLICA staining revealed that 
effector caspases were activated similarly (Figure 3.3D).  Additionally, 
treating cells with TNF-α with or without cycloheximide (CHX) did not 
reveal any differences in apoptosis. CHX alone prevented cell death in these  
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Figure 3.3 Lack of apoptosis phenotype in ΔRING thymocytes. (A) Bulk 
caspase-3-like activity after 8 h treatment. (B) Annexin-V/propidium iodide 
labeling of untreated or treated thymocytes after 8h. (C) TUNEL of 
apoptotic thymocytes after 8h. (D) Annexin-V/propidium iodide labeling 
and FLICA staining of thymocytes left untreated for 24h. (E) TUNEL in 
thymocytes treated with TNF-α/CHX. 
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Figure 3.4 Apoptosis in B-cells. Purified B-cells were treated as indicated 




cells, which suggests that a pro-apoptotic factor may need to be synthesized 
for effective thymocyte apoptosis to ensue (Figure 3.3E).  We also purified 
B-cells from the spleens of WT and ΔRING mice to study apoptosis in this 
cell type. Isolated B-cells of both genotypes activated caspase-3 (Figure 
3.4A) and underwent apoptosis (Figure 3.4B) similarly when treated with 
etoposide or left untreated (Figure 3.4).   
Collectively, the data here imply that the RING was important for 
XIAP protein stability in thymocytes, but that its removal affected neither 
the induction of caspases nor apoptosis in response to several stimuli.  In this 
cell type, removing XIAP RING function did not reveal any specific pro-
apoptotic role for ubiquitin-mediated XIAP turnover during cell death. 
3.4.3 Lymphoid compartments were distributed normally in ΔRING mice 
 
Defective apoptosis can cause imbalances in the cell numbers and cell 
distributions of sites where lymphocytes mature and accumulate, because 
cell death regulates development in hematopoietic cells (Opferman, 2007).  
We determined the cellular compositions of the thymus, spleen and bone 
marrow in mutant mice to see if genetic deletion of the RING altered 
lymphocyte development in situ.  The developing T-cell compartment in the 
thymus was normally distributed in ΔRING mice, as assessed by surface 
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staining of CD4 and CD8 antigens (Figure 3.5); cells bearing either or both 
of these surface makers constitute nearly all of the thymocyte populations.  
Double-positive thymocytes formed the bulk of cells, and single-positive 
cells were normally abundant.  Moreover, total thymocyte counts were 
unperturbed in mutant mice (Figure 3.5).  The normal composition of the 
thymus may reflect the lack of any clear apoptosis defects in cultured 
thymocytes.  Our results accord with a previously published description of 
XIAP-null mice that does not note any defects in thymocyte development 
(Harlin et al., 2001). 
The B-cell lineage differentiates in the bone marrow after embryonic 
development.  We investigated the distribution of major cell types in the 
bone marrow using combinations of fluorophore-conjugated antibodies 
against major surface markers (Figure 3.5).  Hematopoietic stem cells (LSK-
, Sca1+,cKit+), pro-B cells (B220+, CD43+) and pre-B cells (B220+, CD43-
) were present in the bone marrow of ΔRING mice in similar proportions as 
WT mice.  The numbers of mature and immature B-cells were also 
comparable.  Spleens from mutant mice showed normal distributions of the 
major lymphocyte types (Figure 3.6).  The cell types we examined included: 
B-cells (B220+, CD90-) and T-cells (B220-, CD90+); immature  (B220 low,  
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Figure 3.5 Normal thymus and bone marrow in ΔRING mice.  




Figure 3.6 Normal spleens in ΔRING mice. Cellular composition of the 





IgM+) and mature (B220 high, IgM+) B-cells; and helper-T (CD4+, CD8-) 
and cytotoxic-T (CD4-, CD8+) cells (Figure 3.5B).   Taken together, these 
results indicate that deletion of the RING domain did not alter major 
lymphoid compartments in mice. 
3.5 DISCUSSION 
 
 We used thymocytes genetically deficient for XIAP RING ubiquitin-
ligase function to test the hypothesis that RING domains promote IAP 
degradation through autoubiquitination (Yang et al., 2000).  A prevailing 
notion holds that RING-mediated degradation of IAPs might underlie 
apoptosis in thymocytes, since the proteasome is necessary for death in this 
cell type (Grimm et al., 1996; Yang and Li, 2000).  We found that RING 
ubiquitin-ligase activity was indeed the primary determinant of XIAP; 
however, the persistence of XIAP in dying thymocytes did not affect caspase 
activation or enzymatic activity, and ΔRING cells died normally.  These 
results argue that the RING did not exert any appreciable pro-apoptotic 
functions in dying thymocytes.  Our results are more in line with data from 
XIAP-null thymocytes, which die normally, than with thymocytes 
overexpressing human XIAP, which are resistant to death (Conte et al., 
2001).  This highlights a discrepancy between different experimental 
approaches used to study IAP function; heterologous expression systems 
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may interfere with homeostatic mechanisms that control IAP levels, which 
may introduce artifacts that confound the interpretation of results. 
The proteasome is required for apoptosis in thymocytes, but the 
identity of the labile (and presumably anti-apoptotic) factor(s) responsible 
for this phenomenon remains elusive.  Our results argue that XIAP is not 
that factor.  Another candidate is MCL-1, a short-lived anti-apoptotic BCL-2 
family member that is degraded by the proteasome during apoptosis 
following genotoxic stress (Nijhawan et al., 2003).  Although MCL-1 
deficiency in lymphocytes results in increased apoptosis and profound 
reductions in cell numbers, thymocyte development arrests at the double-
negative stage; thus, it is not yet possible to examine the role of MCL-1 
degradation in the double-positive thymocyte population that is most 
sensitive to apoptosis and makes up the bulk of the thymus (Opferman et al., 
2003). 
 Removing the RING domain rendered XIAP more susceptible to 
caspase cleavage, and this accounted for almost all of the processing of 
ΔRING XIAP that occurred during apoptosis. XIAP can homotrimerize 
through its RING; trimerization allows Smac to derepress caspases more 
efficiently in vitro (Gao et al., 2007); however, Smac was downregulated in 
apoptotic ΔRING cells and caspase activity was unaltered in mutant 
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thymocytes.  XIAP also binds cIAP1 through homotypic RING-RING 
interactions (Silke et al., 2005) and XIAP is detected in high molecular 
weight complexes in vivo (Bratton et al., 2001).  It is not known if XIAP 
forms higher order complexes in thymocytes, but the existing data argue that 
a ΔRING mutant would be unable to oligomerize (Silke et al., 2002).  In 
principal, this could render XIAP more susceptible to proteolysis if steric 
hindrance through oligomerization or ubiquitination normally excludes 
caspases from IAP complexes.  This is a plausible explanation because WT 
XIAP was not cleaved by caspases during thymocyte apoptosis.  We also 
note that XIAP downregulation may depend on transubiquitination (e.g., by 
the cIAP1 RING) instead of autoubiquitination, since the ΔRING mutation 
also eliminated the binding surface for cIAP1 (Silke et al., 2005).  Our 
mutant could not rule out this hypothesis, but it could be tested easily in 
cIAP1-null thymocytes (Conte et al., 2006). 
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4 ELEVATED ACTIVITY AND REDUCED 




We used embryonic fibroblasts and stem cells to study apoptosis 
triggered through mitochondria.  We found that absence of XIAP RING 
function led to elevated effector caspase activity during apoptosis.  Deletion 
of the RING did not affect the activation steps that led to caspase-3 
cleavage, however, suggesting that the RING acts on activated effector 
caspases.  Consistent with this notion, we found evidence that XIAP RING 
can serve as a ubiquitin-ligase for caspase-3, because ubiquitination of 
caspase-3 subunits was impaired in apoptotic fibroblasts in the absence of a 
functional XIAP RING.  This phenomenon may underlie the increased 
caspase activity.  In spite of elevated caspase activity and reduced 
ubiquitination, cells tolerated higher caspase activity without any increased 
apoptosis.  Taken together, our findings show that XIAP can regulate 
caspases through ubiquitination, in addition to direct binding and inhibition. 
4.2 INTRODUCTION 
 
This chapter describes experiments designed to investigate the 
function of XIAP ubiquitin-ligase activity in embryonic cells, with an 
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emphasis on stimuli that use factors associated with mitochondria as the 
major means for activating apoptosis.  The mitochondrial pathway to 
apoptosis is well characterized in mouse embryonic fibroblasts (MEFs) and 
embryonic stem (ES) cells, largely because of gene targeting efforts to 
inactivate major components of the pathway.  Genotoxic agents are 
stereotypical activators of the mitochondrial pathway.  Examples include 
etoposide, which inhibits topoisomerase II to promote DNA strand breaks, 
and UVC irradiation, which causes pyrimidine dimers and photoadducts.  
Following genotoxic damage, p53 transduces apoptotic signaling by 
transcriptionally activating BH3-only genes PUMA (Nakano and Vousden, 
2001) and NOXA (Oda et al., 2000).  While MEFs deficient for either gene 
are refractory to apoptosis caused by genotoxic agents, PUMA deficiency 
offers the greatest protection against the widest range of apoptotic stimuli 
(Villunger et al., 2003).  PUMA is upstream of BAX and BAK, because cells 
lacking BAX and BAK together are insensitive to DNA-damage induced 
apoptosis (Wei et al., 2001).  XIAP can inhibit apoptosis caused by 
genotoxic agents by antagonizing caspase-3 when it is overexpressed 
(LaCasse et al., 1998).  We used mouse ES cells and MEFs to test how 
XIAP RING deletion affects the response to stimuli that depend largely on 
factors associated with mitochondria to activate apoptosis. 
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4.3 EXPERIMENTAL PROCEDURES 
4.3.1 Embryonic stem cell culture 
 
The Neo cassette was removed from the hemizygous ΔRING (Neo) 
embryonic stem (ES) cell line #125 by expressing the FLPe recombinase 
(pCAGGS-FLPe, a gift from Chingwen Yang) transiently using the mouse 
ES cell Nucleofection kit (program A-23; Amaxa).  Nucleofected ES cells 
were seeded on mitotically arrested embryonic fibroblasts and colonies were 
allowed to grow for four days. ΔRING (ΔNeo) clones were identified by 
screening replica-plated colonies by Southern blotting of ApaLI digested 
genomic DNA using the same probe described in Chapter 2.  Excision of the 
Neo cassette was verified by direct sequencing, as described in Chapter I.  A 
ΔRING (ΔNeo) clone and the isogenic wild-type E14 parental line used for 
gene targeting were cultured on gelatinized dishes without feeder layers in 
ES cell medium (DMEM with 15% ES-qualified FBS [Chemicon], 100 
U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-Glutamine, 100 mM 
non-essential amino acids, 25 µM β-mercaptoethanol) with 10 ng/mL 
leukemia inhibitory factor (Chemicon).  Mitotically arrested fibroblasts were 
essentially absent from the culture after serially passaging ES cells three 
times in 1:10 splits.  There was no need to re-target the XIAP locus because 
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the E14 ES cell line used for gene targeting had an XY karyotype and hence 
was hemizygous with respect to XIAP. 
4.3.2 Isolation and culture of mouse embryonic fibroblasts 
 
Primary MEFs were isolated from embryos 12.5 days after timed 
matings; the presence of a copulation plug denoted day 0.5.  Livers and 
extraembryonic tissues were dissected away from the embryos, and heads 
were reserved for genotyping.  Embryos were passed twice through 18G 
needles and once through 21G needles before plating on 10-cm dishes.  
Primary MEFs were used through the fifth passage.  Polyclonal pools of 
transformed fibroblasts were obtained by infecting primary MEFs with a 
bicistronic pBabe RasV12/E1A vector (gift from Joe Rodriguez) packaged 
into an ecotropic Phoenix retrovirus.  Primary and transformed MEFs were 
cultured in MEF medium (DMEM with 15% FBS [Hyclone], 100 U/mL 
penicillin, 100 µg/mL streptomycin, 2 mM L-Glutamine, 100 mM non-
essential amino acids, 25 µM β-mercaptoethanol). 
4.3.3 Induction of apoptosis in embryonic cells 
 
ES cells were treated in culture with 100 µM etoposide or 1 µM 
staurosporine for 10 hours, or left untreated in fresh medium.  Primary 
MEFs were treated with 120 mJ/cm2 UVC (Spectrolinker XL-1500; 
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Spectronics Corporation) or mock-irradiated by placing cells in the irradiator 
without UVC light.  Transformed MEFs were treated with 100 µM etoposide 
or 60 mJ/cm2 UVC for 5 hours, or left untreated in fresh medium. 
4.3.4 Apoptosis assays (indirect immunofluorescence) 
 
Trypsinized single cell ES and MEF suspensions were collected with 
any detached dead cells, washed twice in 0.5% BSA/PBS (pH 7.5), and 
fixed in 2% paraformaldehyde in PBS for 10 minutes at 37 C.  Cells were 
washed twice and permeabilized in 90% methanol on ice for 30 minutes, 
before washing twice more.  Cells were blocked in 0.5% BSA/PBS for 10 
minutes at room temperature before incubating with cleaved caspase 
antibodies (caspase-3: Cell Signaling 9661, 1:200 dilution; caspase-8: Cell 
Signaling 18C8, 1:50 dilution) for one hour at room temperature.  
Antibodies were detected using FITC-conjugated secondary antibodies and 
analyzed by flow cytometry.  TUNEL and DEVDase assays were performed 
as described in Chapter 3. 
4.3.5 Analysis of caspase-3 ubiquitination state 
 
Two 90% confluent 10-cm plates of MEFs were irradiated with 120 
mJ/cm2 UVC or mock-irradiated, then harvested after 7 hours; 20 µM MG-
132 was added to cells 30 minutes before collection.  Cell pellets were lysed 
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in hot 1% (w/v) SDS to dissociate protein/protein interactions, then diluted 
ten-fold in 1% Triton-X100 lysis buffer described in Chapter 3.  Lysates 
were clarified by centrifugation and normalized for total protein content 
before rotating overnight at 4 C with a caspase-3 antibody (p32/p17, Cell 
Signaling 8G10 rabbit monoclonal, 1:100).  Immunocomplexes were 
collected with 25 µL of pre-washed protein A-magnetic beads (New 
England Biolabs) by rotating for 2 hours at 4 C.  Beads were collected using 
a magnetic tube rock, washed three times in cold PBS and eluted in SDS-
PAGE sample buffer (New England Biolabs) for 5 minutes at 95 C before 
immunoblotting.  
4.4 RESULTS  
4.4.1 Expression of XIAP ΔRING in ES cells 
 
We investigated the expression of the XIAP ΔRING protein in 
hemizygous ES cells.  We obtained a XIAP ΔRING (ΔNeo) ES cell line by 
transiently expressing the FLPe recombinase to delete the Neo cassette.  
After screening 96 individual colonies, we found most of the colonies 
showed clonal excisions of Neo (Figure 4.1A).  Immunoblotting confirmed 
that the XIAP ΔRING (ΔNeo) allele encoded a truncated protein of the 
expected size in ES cells (Figure  
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Figure 4.1 Excision of Neo cassette from ΔRING ES cells. (A) Southern 
blot of ApaLI-digested DNA from individual ΔRING ES colonies after FLPe 
expression. *, mixed Neo/ΔNeo colony; **, unexcised Neo colony. (B) 
Immunoblot of ΔRING (ΔNeo) ES clone and isogenic WT line. (C) 




4.1B).  The steady state expression level was comparable to that of the full-
length protein in isogenic WT cells.  Thus, removing the RING did not 
influence basal expression of XIAP in ES cells, while ΔRING XIAP is 
expressed at higher basal levels in thymocytes (Figure 3.1).  The expression 
of ΔRING XIAP was lower with Neo still present in the final intron (Figure 
4.1C).  This finding stresses the importance of using a removable positive 
selection cassette in gene targeting. 
4.4.2 Elevated caspase-3 activity in cultured ΔRING embryonic cells 
during apoptosis 
 
We investigated how ES cells and primary MEFs responded to 
different apoptotic stimuli that involve mitochondrial factors.  The 
mitochondrial pathway of apoptosis functions primarily through caspase-9 
and effector caspases-3 and -7, all of which can be inhibited by XIAP in 
vitro.  Caspase-3 enzyme activity was significantly elevated in ΔRING ES 
cells treated with staurosporine or etoposide (Figure 4.2A, left) and in MEFs 
irradiated with UVC (Figure 4.2A, right).  This result was obtained from 
bulk cellular lysates, so it does not offer any insights into caspase activity or 
activation in individual cells.  For this reason, we used an antibody against a 
neoepitope exposed on the large subunit of cleaved, active caspase-3 to  
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Figure 4.2 Elevated caspase activity but normal apoptosis in ΔRING 
embryonic cells. (A) Caspase-3-like enzyme activity in bulk populations of 
WT and ΔRING ES cells treated for 10 hours with etoposide or staurosporine 
(left) and MEFs irradiated with UVC after 8 hours (right). (B) Percentages 
of cells with active caspase-3 detected by indirect immunofluorescence. (C) 
Apoptosis measured by the TUNEL assay. (*) P < 0.05; (**) P < 0.01, 
paired two-tailed Student’s t-test.  
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count the number of apoptotic cells by indirect immunofluorescence and 
determined whether the increased caspase activity was due to a higher rate 
of death for the ΔRING cells.  We found equal numbers of WT and ΔRING 
cells harboring active caspase-3 at times when caspase activity was greater 
in ΔRING cells (Figure 4.2B).  This result suggests that the steps that lead to 
caspase-3 cleavage and activation were not accelerated in embryonic ΔRING 
cells exposed to different stimuli that activated the mitochondrial pathway of 
apoptosis.  Likewise, cells of both genotypes died similarly, as assessed by 
TUNEL (Figure 4.2B).    
In spite of elevated caspase-3 enzyme activity in ΔRING cells, the 
native and cleaved forms of different caspases were expressed similarly in 
untreated and apoptotic ES cells (Figure 4.3A) and primary MEFs (Figure 
4.3B).  XIAP, cIAP1 and Smac/DIABLO became labile during thymocyte 
apoptosis, but the expression levels of these proteins did not change 
appreciably during ES cell apoptosis (Figure 4.3A). 
4.4.3 Impaired caspase-3 subunit ubiquitination in irradiated ΔRING 
fibroblasts 
 
We asked if genetic deletion of the RING affected caspase-3 
ubiquitination in apoptotic cells, because XIAP can polyubiquitinate 
caspase-3 when it is overexpressed (Suzuki et al., 2001).  Additionally, the  
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Figure 4.3 MEF and ES cell immunoblots. (A) ES cells were treated for 
the indicated time (hours) with staurosporine and immunoblotted as 




DIAP1 RING has an essential function in ubiquitinating the caspase-9 
ortholog DRONC in Drosophila (Wilson et al., 2002).  We used an antibody 
that recognizes both full-length caspase-3 and the cleaved large subunit to 
immunoprecipitate the caspase from mock- and UVC-irradiated cells, then 
we immunoblotted with either an antibody against ubiquitin (Figure 4.4A, 
left), or the large subunit of caspase-3 (Figure 4.4A, right).  Both antibodies 
detected a smear that typically indicates polyubiquitination when caspase-3 
was immunoprecipitated from irradiated WT MEFs.  This smear was largely 
absent in irradiated ΔRING MEFs and in mock-irradiated WT and ΔRING 
cells.  These observations suggest that caspase-3 ubiquitination depends on 
both apoptosis and the presence of an intact RING. 
We also measured the chymotrypsin-like activity of the proteasome in 
MEFs.  Proteasome functions were comparable in WT and ΔRING MEFs 
both with and without UVC treatment (Figure 4.4B).  The decrease in 
activity is consistent with caspase-mediated inactivation of the proteasome 
during apoptosis (Sun et al., 2004).  The observed activity reflected genuine 
proteasome activity because lactacystin, a highly specific small-molecular 
inhibitor of the proteasome, abolished the signal (Figure 4.4B). 
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Figure 4.4 Impaired caspase-3 ubiquitination during apoptosis in 
ΔRING MEFs. (A) Caspase-3 was immunoprecipitated from MEFs 7h after 
UVC or mock irradiation and immunoblotted with ubiquitin (left) or active 
caspase-3 antibody (right).  Cells were treated with 20 µM MG-132 for the 
last 30 minutes. (B) Chymotrypsin-like activity of the proteasome after 7h 
UVC treatment with and without lactacystin.  
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Figure 4.5 Apoptosis in Ras/E1A-transformed MEFs. (A) Ras/E1A 
MEFs were treated with etoposide or left untreated for 5 hours before 
assaying DEVDase assay in bulk. Ras/E1A MEFs were treated with 
etoposide, UVC irradiation, or left untreated for 5 hours before assaying 
caspase-3 activation by indirect immunofluorescence (B) and TUNEL (C). 
(*): P < 0.05, by paired two-tailed Student’s t-test. 
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4.4.4 Apoptosis in oncogenically transformed MEFs 
 
MEFs are primed to undergo apoptosis following oncogenic 
transformation (Harrington et al., 1994; White, 2001).  We generated 
polyclonal pools of transformed WT and ΔRING MEFs by retroviral 
transduction of RasV12 and E1A to see if the transformed state might 
sensitize ΔRING MEFs to apoptosis.  Different stimuli that impinge on 
mitochondria caused elevated caspase activity in transformed ΔRING cells 
without increasing apoptosis, albeit at lower drug concentrations and earlier 
times than with primary cells (Figure 4.5).  Similar to primary MEFs, the 
transformed MEFs did not show any enhanced apoptosis in the absence of 
the XIAP RING.  Intriguingly, spontaneous apoptosis in the culture medium 
was subtly elevated in untreated, transformed ΔRING cells.  
4.5 DISCUSSION 
 
This chapter describes genetic evidence for a role of XIAP ubiquitin-
ligase activity in regulating caspase activity in ΔRING MEFs and ES cells.  
Genetic deletion of the XIAP RING domain increased caspase-3 activity in 
response to stimuli that activate apoptosis principally through factors 
associated with mitochondria.  Removing XIAP RING function did not 
affect caspase-3 activation, however.  This argues that the domain did not 
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play a significant upstream role in inhibiting caspase-9, the major activator 
of caspase-3 in MEFs.  Surprisingly, MEFs and ES cells could tolerate 
higher effector caspase activity without any increased death. 
The RING appears to exert its effects on caspase-3 once the caspase 
becomes activated.  Indeed, we observed defective caspase-3 ubiquitination 
in apoptotic ΔRING cells.  This is in line with a prior report showing a role 
for XIAP RING directed ubiquitination of caspase-3 (Suzuki et al., 2001).  
Defective caspase ubiquitination likely explains the increased caspase 
activity seen during apoptosis in ΔRING cells.  It is surprising that the 
expression of the subunits was not elevated appreciably, because 
polyubiquitination generally leads to degradation by the proteasome.  
Additionally, genetic inactivation of the Drosophila DIAP1 RING leads to 
increased DRONC immunostaining that probably reflects increased protein 
expression.  There are some precedents for this unexpected finding, 
however, especially with regard to caspase ubiquitination.  For example, 
polyubiquitinated DRONC persists and is not degraded in cultured 
Drosophila cells in one account (Wilson et al., 2002).  The proteasome itself 
is inactivated during apoptosis activated through the mitochondrial pathway.  
Caspases can cleave key subunits of the 19S regulatory complex that 
recognizes ubiquitinated substrates, thus inactivating the proteasome and 
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leading to an accumulation of polyubiquitinated proteins during apoptosis 
(Sun et al., 2004).  To test this possibility in our system, we measured the 
chymotrypsin-like activity of the proteasome in UVC-irradiated MEFs and 
found that proteasome activity did indeed decrease during apoptosis, 
although it was not abolished completely (Figure 4.4B).   The formation of a 
K48-linked polyubiquitination chain is a potent signal for the proteasome in 
most cases, but it is possible that XIAP can assemble polyubiquitination 
linkages with different topologies.  The polyubiquitination chain assembled 
on the large subunit of caspase-3 awaits a more thorough analysis, perhaps 
by a direct determination of the ubiquitin linkages through mass-
spectrometry.  In principal, the polyubiquitin chain assembled on active 
caspase-3 could impair its ability to form product dimers through steric 
hindrance.  This may explain the lower activity of the caspase in cells that 
retain XIAP E3 ubiquitin-ligase activity.  Collectively, the experiments with 
irradiated fibroblasts imply that deletion of the RING elevated caspase 
activity without strongly affecting the levels of activated caspases, probably 
by interfering with RING-directed ubiquitination that occurs on active 
caspase-3 in normal apoptotic cells.   
Comparisons between apoptotic thymocytes and embryonic cells 
reveal some distinctions in XIAP RING functions between these two cell 
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types.  It is likely that the targets of the XIAP E3-ubiquitin ligase are distinct 
between these cell types: XIAP becomes labile during thymocyte apoptosis 
while caspases are unaffected by a RING deletion (Figure 3.1), while XIAP 
is quite stable and caspases become targets for ubiquitination during the 
death of embryonic cells (Figures 4.3, 4.4A).  The molecular basis for this 
distinction remains unclear.  The proteasome has an uncommonly prominent 
role in enabling apoptosis in thymocytes (Grimm et al., 1996).  Perhaps the 
heightened importance of the proteasome in this cell type enhances the 
natural tendency of RING-containing IAPs to turn over (Silke et al., 2005), 
while the enhanced stability of IAPs in embryonic cells allows them to 
persist and participate in caspase ubiquitination. 
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This chapter describes a novel role for XIAP as a negative regulator of 
TNF-α-dependent apoptosis.  The elevated caspase-3 activity in ΔRING 
cells treated with TNF-α in the absence of NF-κB survival signaling recalled 
the results from Chapter 4, which described similar findings during 
apoptosis through mitochondrial stimuli.  Unlike mitochondrial apoptosis, 
however, apoptosis was genuinely accelerated in ΔRING MEFs during TNF-
α−dependent apoptosis because we observed faster assembly of the 
cytoplasmic complex that activates caspases and initiates apoptosis.  
Cleaved caspases-8 and -3 were detectable in more ΔRING cells over time, 
and TUNEL revealed markedly elevated apoptosis.  We made identical 
observations in XIAP-null cells.  The accelerated TNF-α-dependent 
apoptosis occurred independently or downstream of the JNK signaling 
pathway that is required for initiating apoptosis.  We also obtained similar 
data with transformed ΔRING MEFs undergoing TRAIL-dependent 
apoptosis.  Our genetic data implicate XIAP as a genuine negative regulator 




5.2.1 JNK and NF-κB pathways are antagonistic during TNF-α signaling 
 
The TNF-α cytokine mediates a wide array of functions, including cell 
proliferation, inflammatory cytokine production, and programmed cell 
death.  In MEFs, hepatocytes and many other cell types, soluble TNF-α has 
no cytotoxic effects after ligating its principal receptor, TNF-RI.  This 
occurs because TNF-α signaling simultaneously activates nuclear factor 
kappa-B (NF-κB) pathways and c-Jun-N-terminal kinase (JNK), and these 
two pathways mutually antagonize each other (Bubici et al., 2004).  
Knockout mice have provided most of the evidence that JNK and NF-κB 
pathways act antagonistically during TNF-α signaling.  Mice deficient for 
key components of the NF-κB pathway die in midgestation because of 
massive liver apoptosis; this phenotype is rescued by genetic deletion of 
TNF-α or its cognate receptor, TNF-R1 (Karin and Lin, 2002).  Additionally, 
knockout studies show that the JNK1 isoform is necessary for TNF-α-
dependent apoptosis (Liu et al., 2004).  Much of the TNF-α signaling 
pathway remains unclear, however, and it is still unknown how signaling 
through both JNK and NF-κB is modulated to promote cell survival or death 
in different cell types. 
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The principal role for NF-κB signaling in cells such as MEFs and 
hepatocytes treated with TNF-α appears to involve transcriptional activation 
of factors that actively antagonize the JNK pathway.  MEFs lacking either 
the IκB kinase β (IKKβ), an essential activator of the NF-κB pathway, or 
RelA, a major NF-κB transcription factor, show sustained JNK activity by 
TNF-α (Tang et al., 2001).  This phenomenon has a functional consequence: 
cells lacking either gene die in response to TNF-α alone, whereas WT cells 
remain viable.  RelA-deficient MEFs provide additional evidence that JNK 
signaling has pro-apoptotic functions.  A dominant-negative form of JNK 
kinase (JNKK) prevents JNK activity and inhibits cell death, while a 
constitutively active JNKK-JNK fusion protein promotes cell death with a 
strong apoptotic component (Tang et al., 2001). 
The NF-κB family transcribes a wide range of anti-apoptotic genes 
after TNF-α treatment, including XIAP, cIAP1, BCL-2, BCL-XL, and c-FLIPL 
(Tang et al., 2001).   It is currently unclear which factors are the most 
important antagonists of JNK apoptotic signaling in MEFs treated with 
TNF-α.  Intriguingly, XIAP is the only known NF-κB target that can inhibit 
both JNK signaling and apoptosis when overexpressed (Tang et al., 2001), 
although JNK activation is normal in XIAP-null cells (Harlin et al., 2001).  
The precise mechanism how JNK promotes apoptosis is still unclear, but one 
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candidate molecule in the pathway is the E3 ubiquitin-ligase, Itch (Chang et 
al., 2006).  JNK phosphorylates and activates Itch, which in turn directs the 
assembly of a polyubiquitin chain on c-FLIPL that leads to its degradation by 
the proteasome.  This facilitates cell death because c-FLIPL is a NF-κB 
survival target that interferes with caspase-8 activation and prevents the 
initiation of the TNF-α-dependent cell death program (Irmler et al., 1997). 
5.2.2 TNF-α-dependent apoptosis requires sequential complexes 
 
TNF-α triggers apoptosis in MEFs only when the NF-κB pathway is 
inhibited by blocking global protein synthesis (e.g., with cycloheximide) or 
by inactivating specific components of the pathway (Beg and Baltimore, 
1996).  TNF-α-dependent apoptosis proceeds through two sequential 
signaling complexes (Micheau and Tschopp, 2003).  The first, “Complex I”, 
is assembled proximal to the cell membrane immediately after receptor 
ligation.  Complex I consists of the receptor, TNFR-1; the receptor 
interacting protein 1 (RIP1) kinase; the TNFR-associated death domain 
(TRADD) adaptor protein; and the TNFR-associated factor 2 (TRAF2), a 
RING ubiquitin-ligase.   TRAF2 assembles a K63-linked ubiquitin chain on 
RIP1, which in turn recruits IKK to initiate NF-κB signaling.  Intriguingly, 
cIAP1 is efficiently recruited to Complex I only when NF-κB signaling is 
intact.  TNFR-1, RIP, and TRADD undergo complex post-translational 
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modifications in Complex I that include ubiquitination (Micheau and 
Tschopp, 2003).  Caspase-8 and the FADD adaptor protein are 
conspicuously absent from Complex I regardless of NF-κB status (Micheau 
and Tschopp, 2003).  In contrast, these proteins are immediately detected in 
complex with the Fas receptor when cells are treated with agonistic Fas 
antibody (Kischkel et al., 1995).  This finding highlights the added 
complexity of TNF-α-dependent apoptosis. 
A second complex, Complex II, is detectable in the cytoplasm starting 
several hours after Complex I forms at the membrane (Micheau and 
Tschopp, 2003).  In the absence of NF-κB signaling, Complex II contains 
TRADD, RIP1, caspase-8, and FADD, and c-FLIP.  Recruitment of TRADD 
and RIP1 to Complex II coincides with their dissociation from Complex I, 
while caspase-8 recruitment requires homotypic DED-DED interactions with 
FADD.  Complex II is the activating platform for caspase-8; its assembly 
leads to caspase-8 cleavage and apoptosis.  When NF-κB signaling is intact, 
however, Complex II contains much greater levels of c-FLIPL because c-
FLIPL is a transcriptional target of NF-κB.  The presence of c-FLIPL 
antagonizes caspase-8 activation to promote cell survival (Micheau and 
Tschopp, 2003).  In fact, the levels of c-FLIP seem to determine if caspase-8 
is activated during TNF-α signaling: downregulating c-FLIP through the 
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ubiquitin system (Chang et al., 2006), or by preventing its synthesis (Kreuz 
et al., 2001), correlates tightly with caspase activation.  Additionally, 
knockdown of c-FLIP by short interfering RNAs (siRNAs) substitutes for 
cycloheximide in promoting apoptosis through TNF-α (Wang et al., 2008). 
5.2.3 Involvement of IAPs in TNF-α apoptosis 
 
Recent studies using small-molecule IAP antagonists have revealed 
IAPs to be central negative regulators of TNF-α-dependent apoptosis.  Even 
though IAP antagonists were designed using structural studies of the 
Smac/XIAP-BIR3 interaction, IAP antagonists also bind other IAPs with 
high affinity (Vucic and Fairbrother, 2007).  IAP antagonists can displace 
caspase-3 from XIAP (Li et al., 2004), promote cIAP1/2 autoubiquitination 
and degradation by the proteasome (Varfolomeev et al., 2007; Vince et al., 
2007), while probably exerting other effects.  IAP antagonists synergize with 
TNF-α and a related death ligand, TRAIL (TNF-related apoptosis inducing 
ligand) to induce apoptosis in a variety of cancer cell lines, while exerting no 
cytotoxic effects in primary skin fibroblasts  (Li et al., 2004).  
Downregulation of cIAP1/2 by IAP antagonists can initiate apoptosis in an 
NF-κB-dependent manner by transcriptionally upregulating TNF-α, which 
then appears to kill cells in an autocrine fashion (Petersen et al., 2007; 
Varfolomeev et al., 2007; Vince et al., 2007).  Upregulation of TNF-α 
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occurs in part through a non-canonical (e.g., RIP1-independent) NF-κB 
pathway that is dependent on NIK1 (NF-κB-interacting kinase) as an 
upstream activator.  NIK1 is usually undetectable in cells because cIAP1/2 
RING-dependent ubiquitination targets it for degradation in the proteasome; 
however, depletion of cIAP1/2 by IAP antagonists stabilizes NIK to activate 
NF-κB signaling (Varfolomeev et al., 2007; Vince et al., 2007).   
This model of IAP antagonist activity invokes a pro-apoptotic role for 
NF-κB in upregulating TNF-α, which is surprising because NF-κB has pro-
survival functions in virtually every other context.  A novel mechanism for 
activating caspase-8 during TNF-α-dependent apoptosis was uncovered 
recently by studying IAP antagonists.  Depleting cIAP1/2 by IAP 
antagonists (or siRNA silencing) liberates RIP1 from Complex I, allowing it 
to form a new complex in the cytosol with FADD that promotes caspase-8 
activation.  This complex is distinct from Complex II because it is not 
inhibited by c-FLIP; instead, cIAP1/2 control its formation. 
5.2.4 Pro-apoptotic role of cIAP1 RING in signaling through TNF-R2 
 
The cIAP1 RING has a pro-apoptotic role in the TNF-α-dependent 
apoptotic program signalled through TNF-RII, the second major TNF 
receptor (Li et al., 2002).  Unlike ubiquitous TNF-R1, expression of TNF-
RII is restricted to certain cell types including myeloid cells, T- and B-cells.  
 116 
Ligation of TNF-RII potentiates pro-apoptotic signaling through TNF-R1, 
although it does not appear to directly activate caspase-8 (Zheng et al., 
1995).  TNF-RII lacks death domains that can recruit TRADD; instead, it 
binds TRAF2 directly to initiate signaling.  TRAF2 protects cells from TNF-
α-dependent apoptosis at least in part by activating NF-κB survival 
signaling, and TRAF2-null animals die from rampant TNF-α-dependent 
apoptosis (Yeh et al., 1997).  Specifically ligating the TNF-RII recruits 
TRAF2 and cIAP1/2 to the receptor, leading to downregulation of TRAF2.  
This occurs because the cIAP1 RING is a ubiquitin-ligase that assembles a 
polyubiquitin chain on TRAF2 that marks it for degradation by the 
proteasome (Li et al., 2002).  cIAP1 RING mutants function as dominant-
negative proteins that prevent TRAF2 downregulation and delay TNF-α 
apoptosis.  The cIAP1 RING also targets ASK1, a MAPK kinase kinase in 
the JNK pathway, for polyubiquitination and degradation (Zhao et al., 2007).  
Normally, ASK1 degradation would attenuate JNK signaling during TNF-α 
signaling; however, cIAP1-null B-cells show stabilized ASK1 after TNFR-II 
ligation and persistent JNK signaling (Zhao et al., 2007).  It is unclear if this 
phenomenon has a pro-apoptotic consequence.  Thus, IAP RINGs can act 
pro-apoptotically in some circumstances, by targeting anti-apoptotic 
molecules such as TRAF2 for degradation. 
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5.3 EXPERIMENTAL PROCEDURES 
5.3.1 Induction of death receptor apoptosis 
 
Primary MEFs were treated with 100 ng/mL recombinant murine 
TNF-α (Peprotech) and 1 µg/mL cycloheximide (“CHX”, Sigma).  
Transformed MEFs were treated with 100 ng/mL TNF-α with and without 1 
µg/mL CHX for 3 hours, or 50 ng/mL recombinant murine “SuperKiller” 
TRAIL (Alexis) for 10 hours. 
5.3.2 Immunoprecipitation of the caspase-8 activating complex 
 
To immunoprecipitate caspase-8 complexes, primary MEFs were 
treated with TNF-α/CHX and harvested by scraping detached and adherent 
cells from two 10-cm plates per treatment.  Cell lysates were prepared in 
lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 0.2% Nonidet P40, 10% 
glycerol) supplemented with protease inhibitors, and then snap-frozen in 
liquid nitrogen.  Lysates were thawed in ice water, clarified by 
centrifugation and normalized for total protein content (600 µg per sample) 
before incubating overnight with a FADD (Santa Cruz M-19 goat 
polyclonal, 2 µg) or RIP1 (BD Biosciences, 1:100 dilution) antibody.  
Immunocomplexes were collected as described in Chapter 4, except using 
protein G-magnetic beads (New England Biolabs). 
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5.3.3 Stable knockdown of RelA by shRNA 
 
Ras/E1A-transformed MEFs were transduced with knockdown 
retroviruses (pMLP-empty or pMLP-RelA-shRNA; GFP produced by IRES) 
produced by the Phoenix ecotropic packaging line.  Transduced cells were 
collected by sorting GFP-positive cells.  Transduced cells were seeded in 60-
mm plates and treated with 100 ng/mL TNF-α alone for 3 hours, before 
assaying DEVDase activity. 
5.3.4 Rescue experiment 
 
Primary MEFs were transduced with retroviruses produced by 
packaging pBabe Puro N-myc XIAP WT, XIAP ΔRING, or empty vector in 
the Phoenix ecotropic packaging line.  After 24 hours, transduced cells were 
selected in 1 µg/mL puromycin for three days.  Cells were treated with TNF-
α/CHX for 8 hours and assayed for caspase-3 activity as described above. 
5.3.5 Transient JNK assay 
 
Primary MEFs were seeded in 6-well plates and treated with 100 
ng/mL TNF-α alone.  Cells were collected by scraping directly into 
microcentrifuge tubes, which were flash frozen in liquid nitrogen and used 
for immunoblotting as described above. 
 119 
5.3.6 NF-κB luciferase assay 
 
WT and ΔRING MEFs were transiently transfected with the pNF-κB 
Luc reporter plasmid (Clontech) using the Nucleofector MEF Kit 2 (Amaxa; 
program A-23).  24 hours later, MEFs were treated for 4 hours with 100 
ng/mL TNF-α; 100 ng/mL TNF-α and 1 µg/mL CHX; or left untreated in 
fresh medium.  Cells were harvested and lysed in DEVDase lysis buffer as 
described above.  Cell lysates (30 µg/30 µL) were incubated with equal 
volumes of luciferase substrate solution (Stratagene), before measuring 
luciferase activity in a plate reader set to luminometer mode. 
5.4 RESULTS 
5.4.1 Deletion of XIAP RING sensitizes primary MEFs to TNF-α apoptosis 
 
We treated WT and ΔRING MEFs with TNF-α and cycloheximide 
(CHX) to activate death receptor apoptosis, and found mutant cells to be 
much more responsive to death.  This was evident by the increased number 
of cells with apoptotic morphology, or that had detached from the dish 
(Figure 5.1). Additionally, we found significantly elevated caspase-3 activity 
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Figure 5.1 Sensitivity to TNF-α-dependent death in ΔRING MEFs. 
Brightfield micrographs of WT and ΔRING MEFs treated with TNF-α/CHX 
for the indicated times. 
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Figure 5.2 TNF-α-dependent apoptosis was accelerated in ΔRING 
MEFs. (A) Caspase-3-like enzyme activity in bulk cellular lysates after 8h 
TNF-α/CHX treatment. (B) Percentages of cells with cleaved caspase-8 as 
determined by indirect immunofluorescence over time. (C) Caspase-3 
activation measured by indirect immunofluorescence. (D) Apoptosis 
measured by TUNEL staining. (*): P < 0.05; (**): P < 0.01, by two-tailed 















in ΔRING cells (Figure 5.2A).  This result recalled the greater caspase 
activity described in Chapter 3, when apoptosis was triggered by stimuli 
with a strong mitochondrial signaling component.  Unlike mitochondrial 
apoptosis, however, treatment with TNF-α/CHX accelerated different 
markers of apoptosis in ΔRING MEFs.  Cleaved initiator caspase-8 was 
detected by indirect immunofluorescence in greater percentages of ΔRING 
cells over time (Figure 5.2B).   Caspase-3 activation was accelerated, as 
evidenced by the increased number of cells stained by the CM1 antibody 
that recognizes the cleaved large subunit of caspase-3 (Figure 5.2C).  
Finally, TUNEL revealed that ΔRING MEFs had undergone more apoptosis 
(Figure 5.2D). 
It is unclear if caspase-8 must undergo intrachain proteolysis before it 
can cleave and activate caspase-3 during death receptor apoptosis.  To verify 
that the enhanced cleavage of caspase-8 detected by immunofluorescence 
reflected genuinely accelerated activation, we decided to immunoprecipitate 
the cytoplasmic complex (Complex II) that recruits and activates caspase-8 
after TNF-α/CHX treatment (Micheau and Tschopp, 2003).  We used 
FADD, a requisite cofactor for caspase-8 activation in this cell type, to 
immunoprecipitate the complex to study recruitment of key components  
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Figure 5.3 Faster assembly of caspase-8 activating complex in ΔRING 
MEFs. WT and ΔRING MEFs were treated with TNF-α/CHX for the 
indicated times, and the assembly of the complex that activates caspase-8 
was studied by coimmunoprecipitation using a FADD (A) or RIP1 antibody 
(B). The native form of cIAP1 is indicated by an arrowhead. 
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because it is unique to Complex II.  Both full-length and cleaved caspase-8 
were readily detected in complex with FADD after 4 hours in ΔRING cells; 
this was evident after 6 hours in WT cells upon longer exposure of the 
immunoblot (Figure 5.3A).  Likewise, a higher molecular weight form of 
cIAP1 was recruited to the complex more quickly in ΔRING cells.  
Intriguingly, this form of cIAP1 appeared with comparable kinetics in cells 
of both genotypes (Figures 3.1A; 5.7), but was recruited more quickly to the 
caspase-8 activating complex in ΔRING cells.  The short form of c-FLIP (c-
FLIPs) was bound at all times to FADD in cells of both genotypes.  
Similarly, RIP1 pulled down greater amounts of cIAP1 in ΔRING MEFs 
after TNF-α/CHX treatment (Figure 5.3B).  Taken together with the 
immunofluorescence data, these results argue that the increased apoptosis in 
ΔRING cells indeed reflected an accelerated activation of cell death 
signaling pathways. 
5.4.2 Transformed ΔRING MEFs are sensitized to TNF-α apoptosis after 
RelA-knockdown 
 
 Inhibiting all translation with cycloheximide probably has far-
reaching effects in a cell beyond preventing the synthesis of pro-survival 
NF-κB targets.  To rule out off-target effects of CHX, we inactivated NF-κB 
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specifically by stably expressing a short hairpin interfering RNA against 
RelA, one of the principal members of the family of NF-κB transcription 
factors.  We used Ras/E1A-transformed MEFs for this experiment.  RelA 
knockdown mimicked CHX treatment, as evidenced by increased caspase-3 
activity in ΔRING cells treated with TNF-α alone (Figure 5.4).  This result 
suggests that ΔRING functioned specifically in TNF-α−dependent apoptosis 
and independently of any non-specific effects of CHX.  
5.4.3 XIAP-null MEFs were also sensitized to TNF-α-dependent apoptosis 
 
 We reasoned that the hypersensitivity to TNF-α apoptosis would be 
observed in XIAP-null fibroblasts if the XIAP RING were a true negative 
regulator of apoptosis in this context.  We isolated primary MEFs from a 
mouse engineered to lack XIAP expression by homology-based elimination 
of the first exon (Harlin et al., 2001).  Immunoblotting verified the absence 
of XIAP protein in these cells (Figure 5.5E).  Treatment with TNF-α/CHX 
revealed that the XIAP-null MEFs were as sensitized to apoptosis as cells 
lacking the RING alone.  Caspase-3 enzyme activity increased (Figure 
5.5A), cleaved caspases-8 and -3 were detected in more cells (Figure 5.5B, 
C), and TUNEL revealed heightened apoptosis (Figure 5.5D).  Thus, XIAP 
was a genuine negative regulator of TNF-α-dependent on its RING domain. 
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Figure 5.4 Greater TNF-α-dependent caspase-3 activity in ΔRING cells 
lacking RelA.  Caspase-3-like activity measured from Ras/E1A-transformed 




Figure 5.5 Sensitivity to TNF-α apoptosis in XIAP-null MEFs. (A) 
Caspase-3 activity measured in bulk lysates after 8h treatment with TNF-
α/CHX. (B) Caspase-8 cleavage as assayed by indirect immunofluorescence. 
(C) Caspase-3 cleavage detected by indirect immunofluorescence. (D) 
Apoptosis as measured by the TUNEL assay. (E) Immunoblots of MEFs 
treated with TNF-α/CHX for the indicated times. (*): P < 0.05, two-tailed 
paired Student’s t-test. 
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5.4.4 The XIAP ΔRING mutation was not dominant in TNF-α apoptosis 
 
We used retroviral transduction to complement ΔRING MEFs with a 
full-length XIAP construct containing a functional RING domain, in an 
attempt to rescue the apoptosis phenotype in these cells.  Reintroducing full-
length XIAP to ΔRING cells reduced caspase-3 activity to the normal levels 
seen in WT cells during apoptosis (Figure 5.6).  Ectopic ΔRING XIAP did 
not function as a dominant-negative inhibitor of the endogenous XIAP 
RING, because WT cells did not show elevated caspase-3 activity when we 
expressed a ΔRING construct.  Ectopic expression of XIAP ΔRING also 
lowered caspase-3 activity in ΔRING cells, although not to the same extent 
as the XIAP WT construct.  This may be explained by the greater abundance 
of ectopic ΔRING protein compared to ectopic full-length protein.  XIAP 
has well-documented anti-apoptotic effects when overexpressed, and the 
decreased caspase-3 activity in ΔRING-overexpressing, ΔRING MEFs may 
reflect this phenomenon.  The differences in expression may be an artifact 
from using strong retroviral promoters, since WT and ΔRING proteins are 
expressed at comparable basal levels when transcribed from the endogenous 




Figure 5.6 Rescue experiment.  MEFs were retrovirally transduced with 
the indicated vectors, then treated with TNF-α/CHX for 8 hours before 
assaying caspase-3 activity. 
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5.4.5 Normal expression of components of TNF-a apoptotic pathway 
 
We investigated the expression levels and behaviors of key 
downstream components of the TNF-α apoptotic program (Figure 5.7).  The  
principal TNF receptor in MEFs, TNF-R1, was expressed comparably in 
cells of both genotypes.  Other key cytoplasmic components of the receptor 
complex were as well, including TRAF2, FADD, and c-FLIP (the large form 
of which was degraded during apoptosis).  RIP kinase plays a key role in 
promoting NF-κB signaling and inhibiting apoptosis in TNF-α treated cells, 
and it is inactivated by caspase-8 cleavage (Lin et al., 1999) and proteasomal 
turnover (Wertz et al., 2004).  The basal levels of RIP1 were similar in WT 
and mutant cells, though it was completely cleaved in ΔRING MEFs at a 
time (8h) when most of the cells were apoptotic.  The XIAP RING functions 
anti-apoptotically in primary hepatocytes treated with TGF-β by targeting 
TAK1 (a MAPK kinase kinase in the JNK pathway) for degradation and 
thereby attenuating apoptosis through the JNK pathway (Kaur et al., 2005).  
We investigated the expression of this protein in ΔRING cells, since elevated 
levels of TAK1 might sensitize cells to JNK activation and hence apoptosis 
in the absence of NF-κB signaling.  However, there was no difference in 
TAK1 expression in the mutant cells (Figure 5.7).  NIK was upregulated 
similarly in WT and ΔRING cells.  This seems to argue against any role for  
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Figure 5.7 TNF-α  apoptosis immunoblots. MEFs were treated with TNF-
a/CHX for the indicated times before immunoblotting with as specified. 
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the ΔRING mutation in NIK-mediated upregulation of TNF-α and apoptosis 
seen after IAP antagonist treatment (Varfolomeev et al., 2007; Vince et al., 
2007). 
Both WT and ΔRING XIAP were cleaved during apoptosis, while 
cIAP1 and the BIR-containing protein Survivin were downregulated 
similarly in both genotypes (Figure 5.7).  The expression of Smac/DIABLO 
was unchanged between WT and ΔRING cells.  Immunoblotting confirmed 
the immunofluorescence data, by demonstrating enhanced caspase-3 
cleavage that was evident after 4 hours of treatment with TNF-α/CHX.  
Additionally, the expression of the native form of caspase-8 strongly 
decreased after 8 hours in ΔRING cells (Figure 5.7).  Anti-apoptotic BCL-XL 
expression was elevated somewhat after 4 hours in ΔRING cells, but the 
significance is unclear because apoptosis was already underway. 
5.4.6 Normal JNK activation and NF-κB signaling in ΔRING MEFs 
 
Since the key components that activate or inhibit JNK were similarly 
expressed in WT and ΔRING MEFs, we predicted that JNK activation would 
occur normally in ΔRING MEFs.  Indeed, the activating phosphorylations of 
different JNK isoforms appeared with identical kinetics in TNF-α/CHX 
treated ΔRING MEFs (Figure 5.7).  Surprisingly, this was evident at a time 
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(4h) when there were already differences in apoptosis between the two 
genotypes.  We also observed normal JNK phosphorylation in XIAP-null 
cells (Figure 5.5E).  The phosphorylation status of JNK is transient when the 
NF-κB pathway is intact, and sustained in its absence (Tang et al., 2001).  
This occurs because NF-κB signaling prevents the accumulation of reactive 
oxygen species that would otherwise inactivate MAP kinase phosphatases 
(Kamata et al., 2005).  Treatment with TNF-α alone elicited transient JNK 
phosphorylation in ΔRING MEFs that was indistinguishable from WT cells 
(Figure 5.8A).  This result implies that NF-κB signaling remained intact in 
MEFs when the XIAP RING was genetically deleted, because transient JNK 
phosphorylation is a readout for NF-κB function.   
We also measured NF-κB activity in MEFs using a reporter plasmid 
where the expression of luciferase was driven by optimal NF-κB responsive 
elements.  Treating MEFs with TNF-α alone provoked a strong increase in 
the luciferase signal in cells of both genotypes, while TNF-α together with 
CHX yielded essentially the same signal as no treatment at all (Figure 5.8B). 
Taken together, these results suggest that there was no general propensity for 
ΔRING cells to activate JNK, or maintain activated JNK.  The mechanism 
that promoted enhanced caspase activation in ΔRING and XIAP-null cells 
probably acted independently or downstream from signals that activated  
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Figure 5.8 NF-κB signaling appeared intact in ΔRING MEFs. (A) WT 
and ΔRING MEFs were treated with TNF-α alone for the indicated times 
before immunoblotting. (B) MEFs were transfected with a NF-κB luciferase 
reporter 24 hours prior to assessing NF-κB activity 4 hours after treatment as 
indicated. 
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JNK.  JNK activation is normal in TNF-α-treated MEFs from the XIAP-null 
mouse (Harlin et al., 2001), and we have now shown these cells to be 
sensitized to TNF-α apoptosis. 
5.4.7 Transformed ΔRING MEFs were sensitized to TRAIL apoptosis 
 
TRAIL is a member of the TNF-α superfamily of death receptor 
ligands with potential therapeutic applications, because it can preferentially 
trigger apoptosis in many transformed cell types while leaving normal cells 
unharmed.  The reasons behind this phenomenon are unclear, although there 
are some clues.  E1A, c-Myc and other factors that enforce cycling can 
prime mitochondria to activate caspase-3 further, by shifting BAK into a 
poised, activated state (Nieminen et al., 2007).  Furthermore, E1A 
expression leads to transcriptional upregulation of caspases and thus 
sensitizes fibroblasts to apoptosis (Nahle et al., 2002).  We used the 
Ras/E1A-transformed MEFs described in Chapter 3 to test whether genetic 
deletion of the XIAP RING can sensitize MEFs to TRAIL-mediated 
apoptosis.  Recombinant TRAIL alone elicited apoptosis in both WT and 
ΔRING Ras/E1A MEFs, but ΔRING cells were significantly more 
responsive.  Bulk caspase-3 activity increased (Figure 5.9A), and caspases-8 
and -3 were detected in greater percentages of ΔRING cells (Figure 5.9B, C).  
Cell death was also elevated in mutant MEFs (Figure 5.9D).  The data from  
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Figure 5.9 Hypersensitivity to TRAIL in transformed ΔRING MEFs. 
(A) Caspase-3 activity as measured in bulk. Indirect immunofluorescence 
was used to count the number of cells with cleaved caspase-8 (B) and 
caspase-3 (C). (D) Apoptosis as measured by TUNEL.  Cells were treated as 
described in Experimental Procedures. (*): P < 0.05; (**): P < 0.01, two-
tailed paired Student’s t-test. 
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RING-mutant cells imply that the RING negatively regulates TRAIL 
apoptosis, as well as TNF-α.  Ras/E1A transformation also rendered MEFs 
more susceptible to TNF-α/CHX apoptosis.  The differences in caspase-3 
activity were still apparent between WT and ΔRING cells, but they were 
detectable at earlier times (Ras/E1A: 3 hours, primary: 8 hours).  
Intriguingly, mutant cells also showed a subtle but significant increase in 
caspase-3 activity in response to TNF-α alone.  Similar observations were 
made using immortalized cIAP1-null MEFs (Vince et al., 2007).  These 
results also accord with a genetic argument that that XIAP non-redundantly 




Our experiments with XIAP ΔRING and knockout cells implicate the 
XIAP RING as a novel negative regulator of TNF-α-dependent apoptosis in 
MEFs.  This phenotype was not noted in the initial description of the XIAP-
null mouse (Harlin et al., 2001).  The published account describes normal 
JNK activation and concludes that TNF-α apoptosis is unaltered in XIAP-
null cells.  This finding is consistent with our observations, since the 
activating phosphorylations on JNK occurred with normal kinetics in cells 
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from the published XIAP-null mouse (Figure 5.5) and the ΔRING mouse 
(Figure 5.7).  Furthermore, since loss of RING function mimics a complete 
null allele in TNF-α-dependent apoptosis, the ΔRING mutation constitutes a 
genuine loss-of-function. 
We failed to identify any differentially expressed proteins in the TNF-
α effector pathways that would readily explain the sensitivity to TNF-α 
apoptosis.  All of the key players in the JNK pathway were present in equal 
amounts in unstimulated MEFs of both genotypes, and the only differences 
(e.g., RIP1 cleavage and TAK1 disappearance after 8h in ΔRING MEFs) 
were evident at a time when most of the mutant cells were dead.  Previous 
work identified XIAP as a NF-κB target that specifically antagonized JNK 
activity (Tang et al., 2001).  This conclusion is based on overexpression 
studies in MEFs.  Although we did not do a JNK assay, the activation of 
JNK by upstream kinases occurred normally, as assessed by immunoblotting 
with a phosphorylation-specific antibody.  Based on this result and other 
published findings, we conclude that the sensitivity to TNF-α-dependent 
apoptosis occurs downstream or independently of the signals that activate 
JNK. 
It is unclear if caspases can account for the hypersensitivity to TNF-α 
apoptosis in XIAP loss-of-function MEFs.  Caspase-3 ubiquitination is 
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probably impaired during TNF-α apoptosis, as we demonstrated with UVC 
irradiation (Figure 4.4A).  There is evidence that caspase-8 can be activated 
by caspase-6 in a feedback mechanism (Murphy et al., 2004).  This may 
account for some of the accelerated apoptosis if XIAP RING normally 
ubiquitinates and inhibits other effector caspases.  It seems more likely that 
the differences in apoptosis arise at a point proximal to the receptor, because 
we noted that Complex II assembled more rapidly in ΔRING cells.  It is also 
possible that the effects are indirect.  XIAP and cIAP1 can heterodimerize 
through RING-RING interactions (Silke et al., 2005).  If this interaction 
were necessary for cIAP1 localization or anti-apoptotic functions, such as 
those discussed in the chapter introduction, then removing the XIAP RING 
may sensitize cells to TNF-α-dependent apoptosis indirectly.  However, 
XIAP does not associate with the TNF-R1 complex, and attempts to 
investigate the subcellular localization of endogenous cIAP1 in ΔRING cells 
were stymied by the lack of a suitable antibody for immunofluorescence.  
Perhaps this matter will be resolved as better tools are developed.  
The sensitivity to death receptor apoptosis extended to TRAIL as 
well, as demonstrated by the experiments with oncogenically transformed 
MEFs in Figure 5.8.  This is consistent with prior experiments showing that 
deletion of the XIAP locus by homologous recombination sensitizes colon 
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cancer cells to TRAIL (Cummins et al., 2004).  Attempts to extend these 
findings to Fas death receptor signaling were unsuccessful, probably because 
Fas receptor is expressed at very low levels in fibroblasts.  The susceptibility 
to TNF-α or TRAIL apoptosis did not extend to an experimental model of 
septic shock and liver failure triggered by systemic TNF-α administration 
(Figure 2.4).  This difference may stem from the requirement for 
mitochondrial amplification of death receptor signaling in hepatocytes (Yin 
et al., 1999).  Perhaps the sensitizing effects of ΔRING XIAP are not 
sufficient to overcome this threshold. 
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6 LOSS OF XIAP RING FUNCTION IMPROVES 
SURVIVAL IN THE Eµ-Myc LYMPHOMA MODEL 
6.1 SUMMARY 
 
This chapter describes how loss of RING function improves survival 
in the Eµ-Myc model of non-Hodgkin’s lymphoma.  ΔRING mice showed 
significantly longer lymphoma-free survival and lessened incidence of 
leukemia.  There was a reduction in the number of large, proliferating B-cell 
precursors in the bone marrow and in the periphery.  RING inactivation led 
to elevated apoptosis in the population of proliferating, pre-malignant B-
cells in the bone marrow.  Purified B-cells underwent apoptosis more readily 
when cultured without serum.  The data strengthen the notion that the 
ΔRING mutation is an XIAP loss-of-function and show a novel role for 
RING function in tumorigenesis. 
6.2 INTRODUCTION 
6.2.1 The Eµ-Myc lymphoma model 
 
The chromosomal translocations found in hematopoietic malignancies 
have offered a wealth of insights into the signaling pathways misregulated in 
human cancer.  Many common lymphomas and leukemias arise when 
somatic B-cell receptor arrangement goes awry and juxtaposes enhancers in 
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the receptor locus with potent oncogenes (Cory, 1986).  The BCL-2 gene, for 
example, was first cloned at the breakpoint of the t(14;18) translocation 
found in follicular lymphoma, where its expression is harnessed to the IgH 
locus (Tsujimoto et al., 1984).  A t(8;14) translocation is commonly found in 
Burkitt’s lymphoma in humans, and the analogous translocation t(12;15) 
underlies experimentally induced plasmacytomas in BALB/c mice (Adams 
et al., 1983).  This translocation brings the Myc coding sequence under the 
control of the µ intronic enhancer in the IgH locus.  Since the IgH locus 
encodes the heavy chain of the B-cell receptor, the Eµ-Myc translocation 
leads to constitutive misexpression of Myc throughout the stages of B-cell 
development where the B-cell receptor is expressed (typically, the pro-B 
stage and onward) (Harris et al., 1988).  
 Transgenic mice expressing the Eµ-Myc fusion offer clear evidence 
that this translocation can cause lymphoma and leukemia (Adams et al., 
1985).  This mouse transgenically expresses an Eµ-Myc translocation cloned 
from a murine plasmacytoma, and it represents a technological triumph 
because it is one of the first transgenic mice ever created.  Mice harboring 
the Eµ-Myc translocation develop lymphoma and lymphoblastic leukemia, 
but the neoplastic cells (principally, pre-B and B-cells) are distinct from the 
cells that arise in Burkitt’s lymphoma, which affects mostly mature B-cells 
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(Adams et al., 1985).  Better models of Burkitt’s lymphoma have since been 
developed (Kovalchuk et al., 2000), but the Eµ-Myc mouse remains a widely 
used model of non-Hodgkin’s lymphoma. 
 Lymphocytes from Eµ-Myc mice progress through three distinct 
stages (Sidman et al., 1993).  Initially, B-cell precursors hyper-proliferate in 
the bone marrow starting before birth (Langdon et al., 1986).  The expanded 
pool of lymphocytes is comprised principally of pre-B-cells, and some of 
them migrate to the periphery (Sidman et al., 1993).  The leukocyte 
population then returns to near-normal levels, probably because of apoptosis 
in the bone marrow and periphery (Jacobsen et al., 1994).  This occurs partly 
because pre-malignant Eµ-Myc B-cells remain dependent on limiting 
amounts of cytokines for survival signaling (Langdon et al., 1988).  The 
length of this intermediary period varies among individuals.  The final stage 
is marked by emergence of disseminated lymphoma and a pathological 
elevation in the numbers of large, circulating lymphoblasts as the mice 
develop leukemia (Sidman et al., 1993).  Death usually ensues soon after.  
 Lymphoma latency varies among not only different mouse strains, but 
also genetically identical mice from the same inbred strain (Sidman et al., 
1988).  We can make several inferences from these observations.  First, 
genetic modifiers unique to different mouse strains synergize with Eµ-Myc 
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to influence the latency of disease.  Eµ-Myc mice on the C57BL/6 strain, for 
example, live considerably longer than Eµ-Myc BALB/c mice (Sidman et 
al., 1988).  Additionally, the variable latency among inbred mice points to 
the involvement of somatic, tumorigenic mutations that occur stochastically.  
Indeed, cells from the pre-lymphoma stage in Eµ-Myc mice are not 
malignant and do not survive transplantation into compatible hosts (Langdon 
et al., 1986).  Even cells from double transgenic Eµ-Myc/BCL-2 mice are not 
transplantable at early stages, despite their markedly enhanced survival in 
the absence of growth factors (Strasser et al., 1990).  These findings imply 
that three or more oncogenic “hits” may be required to transform 
lymphocytes.  Remarkably, the likelihood that a given Eµ-Myc pre-B cell 
will become malignant is only about 1 in 1010 on a mixed genetic 
background (Harris et al., 1988), and the tumors that do arise are invariably 
of clonal origin (Adams et al., 1985; Harris et al., 1988).   
6.2.2 Apoptosis as a critical modulator of Eµ-Myc lymphoma 
 
There is a wealth of evidence implicating apoptosis as a key modulator 
of lymphoma development in the Eµ-Myc mouse.  The observation that 
BCL-2 synergizes with Eµ-Myc to accelerate lymphoma by increasing the 
survival of transgenic B-cells is a hallmark finding in the cell death field 
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(Strasser et al., 1990; Vaux et al., 1988).  Many other factors related to 
apoptosis are now known to modulate the Eµ-Myc model.  For instance, B-
cells from Eµ-Myc mice undergo spontaneous p53-dependent apoptosis, and 
there is strong selective pressure to inactivate the ARF-Mdm2-p53 axis 
(Eischen et al., 1999) (Eischen et al., 2004; Schmitt et al., 1999).  p53 
deficiency reduces survival of Eµ-Myc mice (Schmitt et al., 1999), while 
loss of Mdm2 prolongs survival by facilitating p53-dependent apoptosis of 
pre-malignant cells (Alt et al., 2003).  Expression of BCL-2 or dominant-
negative caspase-9 phenocopies loss of p53 function in the Eµ-Myc model; 
remarkably, expression of either genes relieves the selective pressure to 
inactive the p53 locus in vivo (Schmitt et al., 2002).  These findings imply 
that p53’s chief tumor suppressor function in Eµ-Myc lymphoma is to 
activate apoptosis through mitochondrial factors and caspase-9.  
Furthermore, BIM appears to be the principal BH3-only factor that activates 
apoptosis in the Eµ-Myc model (Egle et al., 2004). 
6.2.3 XIAP in lymphoid malignancy 
 
Overexpression of XIAP can inhibit cell death in virtually every cell 
culture system (LaCasse et al., 1998), and elevated XIAP expression is 
found in many human tumors (Hunter et al., 2007).  Studies like these 
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implicate XIAP gain-of-function mutations in the development of cancer, 
and led to the development of therapeutic compounds that antagonize IAPs 
to promote apoptosis in human tumors (Vucic and Fairbrother, 2007).  There 
is little experimental evidence linking XIAP function to tumorigenesis, 
however, and much of the data remains circumstantial.  Although transgenic 
mice overexpressing human XIAP in the thymus show increased numbers of 
developing T-cells and resistance to apoptosis (Conte et al., 2001), no 
published mouse models have shown that XIAP can promote tumor 
formation.   
A positional cloning effort identified XIAP deficiency as a genetic 
basis for the human X-linked lymphoproliferative syndrome (Rigaud et al., 
2006).  Lymphocytes in afflicted patients are sensitized to TRAIL and Fas 
death receptor apoptosis and natural killer T-lymphocytes are depleted.  
How enhanced apoptosis leads to lymphoproliferation remains a mystery.  
This report provides the clearest link between XIAP loss-of-function and 
human disease.  The data described in this chapter extend these findings to 
the Eµ-Myc mouse model of lymphoma, and provide genetic evidence 
implicating RING function in inhibiting apoptosis in tumorigenesis. 
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6.3 EXPERIMENTAL PROCEDURES 
6.3.1 Eµ-Myc Mouse Experiments 
 
ΔRING mice were backcrossed to C57BL/6 mice for at least six 
generations before mating with C57BL/6 Eµ-Myc mice purchased from 
Jackson Laboratory (strain B6.Cg-Tg(IghMyc)22Bri/J).  Cohorts of mice 
were monitored for lymphoma-free survival over time before generating a 
Kaplan-Meier survival curve.  Lymphoma was documented in every mouse 
scored as a fatality in the Kaplan-Meier analysis.  Mice were censored from 
analysis when used for breeding or an experiment.  Peripheral blood was 
sampled periodically by retro-orbital eye bleeds and analyzed by the 
Laboratory of Comparative Pathology at Memorial Sloan-Kettering Cancer 
Center.  Analyses included complete counts of major lymphocyte 
populations and viewing of blood smears by pathologists.  
6.3.2 Bone marrow and cultured B-cell experiments   
 
For bone marrow analysis, cell suspensions were flushed from femurs 
and tibias, treated with erythrocyte lysis buffer (9 volumes of 150 mM 
NH4Cl, 1 volume of 130 mM Tris-Cl, pH 7.65), and stained with B220-APC 
(1:50, BD Pharmingen) for 20 minutes on ice to label B-cells.  Cells were 
fixed in 3% paraformaldehyde for 15 minutes at room temperature, 
permeabilized in 2% Triton X-100/PBS for 15 minutes at room temperature, 
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then assayed by TUNEL.  Apoptosis was measured in proliferating B-cells 
by gating large-scattering B220+ cells.  
 Eµ-Myc B-cells were purified from spleen preparations by magnetic 
depletion of non-B-cells, as described in Chapter 3.  An aliquot of cells was 
saved from each preparation to verify the purity of the depleted samples, as 
described in Chapter 3.  Purified B-cells were cultured at a density of 106 
cells/mL in B-cell medium (50% Iscove's MEM, 50% DMEM, 100 U/ml 
penicillin, 100 g/ml streptomycin, 4 mM l-glutamine and 25 µM 2-
mercaptoethanol) in the absence of serum for 3.5 hours, prior to performing 
TUNEL as described in Chapter 3. 
6.4 RESULTS 
6.4.1 The ΔRING mutation improved survival of the Eµ-Myc mouse 
lymphoma model 
 
Removing the RING domain rendered XIAP a worse caspase inhibitor 
in embryonic cells, which suggests that the ΔRING allele is a loss-of-
function. We explored the effects of this mutation on a mouse lymphoma 
and leukemia model where apoptosis has an essential tumor suppression 
function.  By crossing the ΔRING allele onto the Eµ-Myc background and 
following the survival of WT and ΔRING mice over time, we found that 
ΔRING mice showed improved survival on this sensitized background  
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Figure 6.1 Genetic deletion of XIAP RING prolongs life in the Eµ-Myc 
lymphoma model. (A) Kaplan-Meier survival curve of WT and ΔRING 
mice on the Eµ-Myc background. (B) Kaplan-Meier survival curve of WT 
and XIAP-null mice on the Eµ-Myc background. 
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(Figure 6.1A; p = 0.010).  The median survival time for WT mice was 135 
days, whereas median survival time increased to 246 days for ΔRING mice 
on the Eµ-Myc genetic background.  32.0% of ΔRING mice were alive after 
45 weeks, while 8.4% of WT mice survived that long; the number of WT Eµ-
Myc mice still alive was consistent with published data on the comparatively 
resistant C57BL/6 strain (Sidman et al., 1988).  Thus, the survival curve 
demonstrates that inhibiting RING function by genetic deletion can prolong 
survival of Eµ-Myc mice.  Intriguingly, genetic deletion of XIAP may also 
prolong survival on the Eµ-Myc background; however, the significance of 
this observation awaits further monitoring of the colony (Figure 6.1B). 
6.4.2 Decreased incidence of leukemia in ΔRING Eµ-Myc mice 
 
Peripheral white blood cells progress through characteristic stages in 
the course of Eµ-Myc lymphomagenesis (Sidman et al., 1993).  We followed 
progression through these stages by sampling blood at regular intervals from 
WT and ΔRING Eµ-Myc mice.  White blood cell (WBC) counts were 
comparably elevated in young mice of both genotypes (Figure 6.2A).  The 
WBC counts were consistent with those of mice transitioning from the first 
to second stages of disease in the Eµ-Myc model (Sidman et al., 1993).  
WBC counts returned to lower physiological levels by seven weeks of age in  
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Figure 6.2 Lessened incidence of leukemia in ΔRING Eµ-Myc mice. 
White blood cell counts in peripheral blood from mice of indicated ages. 
Bars indicate mean counts. 
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all mice.  The following weeks saw some WT mice begin to develop 
pathological WBC counts characteristic of leukemia, whereas ΔRING mice 
maintained consistently low counts over the same period (Figure 6.2B).  
Large leukocytes typical of lymphoblastic leukemia were noted in peripheral 
blood from all mice with pathologically elevated WBC counts.  Therefore, 
loss of the XIAP RING curtailed leukemia on the Eµ-Myc background. 
6.4.3 ΔRING Eµ-Myc B-cells were sensitized to apoptosis in the bone 
marrow 
 
Proliferating B-cells in Eµ-Myc mice can be distinguished based on 
their increased size (Langdon et al., 1986; Sidman et al., 1993).  This 
population of cells co-labels with BrdU, and represents a significantly larger 
percentage of the Eµ-Myc bone marrow compared to nontransgenic mice 
(Langdon et al., 1986).  In fact, the larger size of Eµ-Myc lymphocytes can 
be used to genotype transgenic mice unambiguously (Harris et al., 1988).  
We isolated bone marrow from Eµ-Myc mice and found decreased numbers 
of large proliferating B-cells in the bone marrow of ΔRING transgenic mice 
of different ages (Figure 6.3A).  The percentages of large B-cells in the bone 
marrow increased with time in mice of both genotypes, but ΔRING mice 
always had fewer large cells.  The fraction of TUNEL-positive, apoptotic 
cells was elevated in the large B-cell population in ΔRING Eµ-Myc mice  
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Figure 6.3 Decreased abundance and increased apoptosis of 
proliferating B-cells in ΔRING Eµ-Myc bone marrow. Histograms 
showing: (A) the percentages of small (resting) and large (proliferating) 
B220+ cells in the bone marrow of age-matched Eµ-Myc mice. (B) TUNEL 
in the large-scattering B220+ cell population. 
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(Figure 6.3B).  These findings support the notion that the ΔRING mutation 
constitutes a loss-of-function allele that can promote apoptosis in vivo. 
6.4.4 Loss of XIAP RING facilitated apoptosis of cultured Eµ-Myc B-cells 
 
Apoptotic Eµ-Myc cells are rapidly cleared by phagocytes in situ 
(Jacobsen et al., 1994).  This observation may explain why TUNEL-positive 
cells were scarce even in the proliferating population of B-cells that 
undergoes high levels of Eµ-Myc-driven apoptosis in the bone marrow 
(Figure 6.3B).  We isolated pure populations of B-cells from the spleens of 
Eµ-Myc mice to characterize apoptosis under cell culture conditions in the 
absence of phagocytes.  Before isolation, the major cell populations in the 
spleens of WT and ΔRING Eµ-Myc mice were distributed similarly (Figure 
6.4A, B) and consistent with a prior account (Langdon et al., 1986).  After 
purifying B-cells, the isolated cells were nearly pure populations of early B-
cells (>95% B220+, CD43-, IgM-) as assessed by flow cytometry.  We 
deprived the purified Eµ-Myc B-cells of serum because B-cells that 
misexpress Myc are strongly sensitized to apoptosis caused by growth factor 
withdrawal (Cherney et al., 1994; Milner et al., 1993).  B-cells isolated from 
ΔRING mice showed significantly greater apoptosis after 3.5 hours of serum 
deprivation in culture (Figure 6.4C; p < 0.01 by two-tailed Student’s t-test).   
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Figure 6.4 ΔRING Eµ-Myc B-cells were sensitized to serum withdrawal. 
(A) Compositions of WT and ΔRING Eµ-Myc spleens as assessed by flow 
cytometry. (B) Distributions of B220+ cells in spleens. (C) B-cells purified 
from spleens were cultured without serum for 3.5 hours before performing 
TUNEL.  Black bars denote mean values. 
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This result is in line with the elevated apoptosis seen in freshly isolated bone 
marrow, and it further supports the notion that loss of XIAP RING function 
sensitizes pre-malignant B-cells to apoptosis. 
6.5 DISCUSSION 
 
XIAP has been implicated in human tumorigenesis and 
lymphoproliferative diseases (Nakagawa et al., 2005; Rigaud et al., 2006; 
Tamm et al., 2000), and inhibiting XIAP and other IAPs with 
Smac/DIABLO-derived peptides (Fulda et al., 2002) or small molecule 
antagonists (Petersen et al., 2007) can reduce tumor xenografts in mice.  To 
our knowledge, there are no reports showing a causative role for XIAP in 
tumor models.  We provide evidence that loss of XIAP RING function 
synergized with Eµ-Myc to enhance survival in a model of lymphoma and 
leukemia.  A prevailing notion holds that XIAP overexpression enhances 
tumor cell survival.  Since deleting the RING rendered XIAP a worse 
inhibitor of caspases, our findings with the Eµ-Myc model are consistent 
with the notion that the ΔRING mutation is a loss-of-function allele.   
 The sensitized Eµ-Myc background was necessary to reveal that loss 
of XIAP RING function has a pro-survival effect in lymphocytes. The 
increased sensitivity to apoptosis when Myc is misexpressed lowers the 
threshold to caspase activation, in part because of Myc-dependent activation 
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of ARF (Eischen et al., 1999). Indeed, improved survival on this background 
is also seen when Mdm2 expression is reduced by genetic deletion (Alt et al., 
2003).  This study also identified decreased numbers of peripheral 
lymphocytes and increased spontaneous apoptosis in cells cultured without 
survival factors.  XIAP ΔRING did not afford as much protection as Mdm2 
deficiency.  This is not surprising perhaps because specific p53-dependent 
apoptosis underlies the death of Eµ-Myc cells (Eischen et al., 1999; Schmitt 
et al., 1999).  Presumably, loss of anti-apoptotic BCL-2 genes would also 
stimulate apoptosis and improve survival on this background.  To our 
knowledge, this experiment has not been done yet.  This would probably 
require adoptive transfer of bone marrow or lymphoma cells because 
knockouts of anti-apoptotic BCL-2 genes result in lethality. 
The molecular basis for our phenotype is unclear.  The mechanism 
may arise from decreased caspase ubiquitination during p53-mediated death 
of Eµ-Myc B-cells.  This hypothesis is testable, but we were unable to obtain 
enough input material from our existing Eµ-Myc colony to investigate 
caspase-3 ubiquitination (the caspase-3 immunoprecipitation described in 
Chapter 4 required 1 mg of input lysate).  Enhanced sensitivity to death-
receptor apoptosis, seen in ΔRING MEFs, may offer some clues into the 
mechanism of prolonged survival.  Myc expression sensitizes cells to TRAIL 
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(Ricci et al., 2007), and loss of the TRAIL (Finnberg et al., 2008) or Fas 
(Zornig et al., 1995) receptors worsens prognosis on a Myc background.  
Unfortunately, we were unable to test this hypothesis because treatment with 
TRAIL, Fas, or TNF-α (all with and without cycloheximide) did not raise 
the levels of apoptosis beyond background levels, even when serum was 
removed.  Others have noted that Eµ-Myc cells do not die readily in 
response to these treatments as well (Finnberg et al., 2008).  It remains 
unclear how death receptors modulate the phenotype of Eµ-Myc mice. 
It is also possible that the XIAP RING has in indirect role in this 
context, through RING-dependent interactions with cIAP1.  cIAP1 was 
recently identified as a ubiquitin-ligase that targets Mad1, an inhibitor of 
Myc, for degradation, thereby enhancing proliferation and colony formation 
(Xu et al., 2007).  This idea is speculative, but perhaps RING-RING 
interactions normally promote the formation of a XIAP/cIAP1 heterodimer 
that enhances cIAP1-dependent ubiquitination of Mad1.  The absence of 
XIAP RING could then inhibit cIAP1-mediated turnover of Mad1 and 
dampen Myc-dependent proliferative signals.  This hypothesis is testable by 
immunoblotting.  
 159 
7 CONCLUDING DISCUSSION AND IMPLICATIONS 
FOR FUTURE RESEARCH  
7.1 Perspective 
 
Previous efforts to study the regulation of apoptosis by XIAP have 
largely focused on how BIR domains bind and inhibit caspases, often by 
relying on overexpression in cancer cell lines and on the biochemical and 
structural analyses of isolated domains (Hunter et al., 2007).  These 
approaches have offered valuable insights into the molecular mechanisms by 
which XIAP may regulate caspases, and they also guided the design of 
small-molecule therapeutics that disrupt BIR/caspase complexes to promote 
apoptosis in tumors (Carter et al., 2005; Petersen et al., 2007; Varfolomeev 
et al., 2007; Vince et al., 2007).  The results from this study emphasize the 
importance of the RING domain, which bestows E3-ubiqutin ligase activity 
on XIAP, for the negative regulation of caspases, cell death and tumor 
suppression by XIAP in vivo.  The RING may be a promising target for 
therapeutic intervention in some cancers because genetic removal of this 
domain limited the abundance of proliferating, pre-malignant B cells and 
prolonged survival in a mouse model of lymphoma, without adversely 
affecting lymphoid cells or causing any other overt negative consequences in 
control mice.  Since we also observed elevated spontaneous apoptosis in 
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transformed ΔRING MEFs, these observations may extend to other 
transformed cells. 
7.2 Comparisons between DIAP1 and XIAP RING function 
 
Studies on the DIAP1 RING in Drosophila show that cells can use 
RING ubiquitin-ligase activity to exert both pro- and anti-apoptotic effects.  
An antiapoptotic role for DIAP1 RING function in healthy cells was 
revealed using mutant animals: point mutations that inactivate key structural 
residues in the DIAP1 RING are lethal as advanced embryos (Lisi et al., 
2000; Wilson et al., 2002), and a ΔRING truncation causes virtually every 
embryonic cell to die by apoptosis (Goyal et al., 2000).  Point mutations that 
inactivate RING ubiquitin-ligase function do not preclude DIAP1 from 
binding the initiator caspase DRONC, but they do prevent 
polyubiquitination of Dronc (Wilson et al., 2002).  The failure to 
ubiquitinate DRONC has catastrophic consequences in tissues like the wing 
imaginal disc: DRONC immunostaining increases dramatically, probably 
through enhanced stability of the protein; effector caspases are activated; 
and cells die by apoptosis (Ryoo et al., 2002; Ryoo et al., 2004).  These 
experiments describe an essential anti-apoptotic function for the DIAP1 
RING in the developing embryo by ubiquitinating DRONC and preventing it 
from triggering apoptosis in cells that should normally live.   
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An opposing pro-apoptotic function for the RING has emerged from 
studies on the DIAP1 antagonist Reaper, which is transcribed only in dying 
cells. Expression of Reaper depletes DIAP1 through RING-dependent 
autoubiquitination, and this leads to apoptosis (Ryoo et al., 2002).  The case 
for a pro-apoptotic DIAP1 RING function is further strengthened by genetic 
interaction studies that show a requirement for Ubcd1, the cognate E2 
ubiquitin conjugating enzyme for DIAP1, in Reaper-dependent apoptosis 
(Ryoo et al., 2002).  Collectively, these experiments imply that the outcome 
and targets of RING-dependent ubiquitination depends on the state of the 
cell: healthy cells can employ the RING to keep caspases in check, and 
dying cells engage it to permanently lower the threshold against cell death. 
How RING ubiquitin-ligase activity regulates apoptosis in 
mammalian cells was largely unknown until now.   There are certain 
parallels between Drosophila and mammalian IAP RING functions, 
especially with regard to ubiquitination substrates.  The first links between 
the ubiquitin system and IAP RING function were described in mouse 
thymocytes (Yang et al., 2000).  RING-dependent autoubiquitination and 
downregulation of XIAP and cIAP1 was proposed as a mechanism 
explaining why the proteasome is required for thymocyte apoptosis (Yang 
and Li, 2000).  Depletion of IAPs through the ubiquitin system does not 
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seem to be a universal phenomenon, however, and some cells still die when 
IAPs are abundantly expressed (ES cells, for example).  In thymocytes, 
increasing the abundance of XIAP by removing the RING did not affect 
apoptosis, however, so it remains unclear why IAPs are degraded so rapidly 
by the proteasome in these cells.  It is possible that the heightened 
importance of the ubiquitin system in thymocytes enhances the natural 
tendency of RING domain IAPs to degrade themselves (Silke et al., 2005).  
The degradation of other IAPs may be sufficient to lower the inhibitory 
threshold against cell death in spite of XIAP persistence.  Moreover, the 
factor(s) that actively promotes IAP turnover during thymocyte remain 
elusive.   
Specific inhibition of XIAP is required for cytochrome c-mediated 
apoptosis in mouse sympathetic neurons, and this occurs by post-
translational downregulation in dying cells (Potts et al., 2003).  Primary 
neuronal cultures from XIAP-null mice die in response to cytochrome c 
injection alone, while WT cells are resistant.  Remarkably, cultured ΔRING 
neurons are as sensitive to cytochrome c injection as knockout cells (M. 
Deshmukh, personal communication).  This strengthens the notion that the 
XIAP RING deletion is a loss-of-function allele, while casting further doubt 
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on the role of ubiquitin-mediated turnover in promoting apoptosis in primary 
cells. 
In addition to autoubiquitination, XIAP can function as a ubiquitin 
ligase for most of its binding partners, at least in overexpression and in vitro 
assays.  The effects can be both pro- and anti-apoptotic.  Ectopically 
expressed XIAP can promote polyubiquitination of caspases-3, -7 and -9, 
and this effect can have anti-apoptotic consequences by antagonizing 
caspase function (Creagh et al., 2004; Morizane et al., 2005; Suzuki et al., 
2001).  We did not observe appreciable increases in the expression levels of 
these caspases, however.  The XIAP RING functions anti-apoptotically in 
primary hepatocytes treated with TGF-β by targeting TAK1 for degradation 
and thereby attenuating apoptosis through the JNK pathway (Kaur et al., 
2005).  We did not see any altered expression of TAK1 in MEFs during 
TNF-α/CHX apoptosis, and it will be worthwhile investigating the 
consequences of the RING mutation in hepatocyte cultures especially since 
cIAP1 overexpression contributes to hepatocellular carcinoma (Zender et al., 
2006).  Anti-apoptotic functions for the RING were inferred from the 
observation that XIAP can polyubiquitinate its antagonist ARTS and target it 
for degradation (Lotan et al., 2005), though it is unclear if Smac/DIABLO is 
a ubiquitination substrate as well (Creagh et al., 2004; MacFarlane et al., 
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2002).  XIAP also acts independently of cell death pathways to influence 
intracellular copper levels through ubiquitin-dependent regulation of the 
copper regulatory protein MURR1, and XIAP-null fibroblasts show modestly 
elevated MURR1 protein expression (Burstein et al., 2004). 
Since the RING can exert pro- and anti-apoptotic effects, we 
engineered a ΔRING allele to genetically investigate the relative 
contributions and outcomes of RING activity in primary cells and in vivo.  
Inactivation of the mouse XIAP RING by gene targeting revealed parallels 
with fruit fly DIAP1 RING function and differences as well.  While DIAP1 
RING mutants die as advanced embryos, ΔRING mice are viable on mixed 
and congenic C57BL/6 backgrounds.  This may reflect different regulatory 
strategies utilized by Drosophila and mice.  Drosophila seems to rely on 
DIAP1 as a central control point in controlling apoptosis: RING-mediated 
suppression of DRONC as a key regulatory step to prevent accidental 
caspase activation (Wilson et al., 2002), and IAP antagonists are absolutely 
required for apoptosis (White et al., 1994).  Many mammalian cells seem to 
control apoptosis initiation more stringently upstream of mitochondria 
(Lindsten et al., 2000; Wei et al., 2001) while particular IAPs (XIAP, cIAP1, 
cIAP2) and IAP antagonists (Smac/DIABLO, Omi/HtrA2, ARTS) are 
dispensable individually for regulating apoptosis during development.  The 
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lack of strong phenotypes in mice deficient for individual negative 
regulators is perhaps not surprising, as cell death pathways are almost 
certainly redundant in comparatively long-lived animals.  Furthermore, it is 
very likely that there are additional negative regulators of apoptosis apart 
from known caspase inhibitors like IAPs.  This is an area of research that 
merits further investigation. 
Nonetheless, we have shown that XIAP RING function influences 
caspase functions in embryonic cells.  Caspase-3 enzyme activity was 
elevated in ΔRING cells in response to diverse apoptotic stimuli and 
irradiated MEFs were defective in caspase subunit ubiquitination.  Unlike 
DIAP1 RING mutant cells, caspase subunit abundance was not dramatically 
altered in apoptotic ΔRING cells, which leaves open the possibility that 
polyubiquitination may not lead to degradation of caspases.  In principle the 
ubiquitination of active caspase-3 by a functional XIAP RING could impair 
the enzymatic activity of a caspase or its ability to form functional dimers, 
although ΔRING cells could tolerate higher caspase activity without 
increased death when cells were killed through the mitochondrial pathway of 
apoptosis.  WT XIAP was not cleaved much during thymocyte apoptosis, 
while cleavage products were detected during TNF-α-dependent apoptosis in 
MEFs.  The presence or absence of a polyubiquitin chain may determine if 
 166 
XIAP can be cleaved by caspases, because XIAP was cleaved by caspases 
only in situations when it was not very labile.   
7.3 IAPs in death receptor signaling 
 
IAPs have diverse regulatory roles in death receptor signaling 
pathways that have become known recently (Li et al., 2004; Varfolomeev et 
al., 2007; Vince et al., 2007).  Much of this evidence comes from studies 
with IAP antagonist compounds that can liberate caspase-3 from XIAP and 
trigger cIAP1/2 autoubiquitination and degradation.  IAP antagonists 
synergize with apoptotic stimuli to induce apoptosis in most human cancer 
cell lines studied so far, and some cell lines are killed by the compound 
alone (Petersen et al., 2007).  Our findings may offer some important 
mechanistic insights into how IAP antagonists induce apoptosis.  cIAP1/2 
are degraded within minutes after IAP antagonist treatment, while XIAP 
remains relatively stable (Varfolomeev et al., 2007; Vince et al., 2007).  The 
authors describe a mechanism where TNF-α is transcribed through a NF-κB-
dependent mechanism (normally inhibited by cIAP1/2), and induces 
apoptosis through autocrine signaling.  While IAP antagonists do not 
strongly promote XIAP degradation, they do bind XIAP very tightly and 
prevent it from binding caspase-3 (Li et al., 2004; Vucic and Fairbrother, 
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2007).  This effect may functionally substitute for genetic deletion of XIAP, 
which we have shown to sensitize cells to TNF-α-dependent apoptosis. 
The mechanism for TNF-α and TRAIL sensitivity remains elusive. 
RING ubiquitin-ligases usually function to regulate the abundance of their 
binding partners, but the differential sensitivity between WT and ΔRING 
cells was not obvious from the protein expression levels of key components 
in the TNF effector pathways.  A proteomics effort may be useful to identify 
proteins that are upregulated in mutant cells during the earliest stages of 
TNF-α apoptosis signaling.  This method may identify misregulated factors, 
normally kept in lower abundance by XIAP RING-mediated turnover, which 
may underlie sensitization.  Alternatively, the mechanism may be 
independent from ubiquitination, and may instead arise instead if factors 
involved in death receptor signaling were mislocalized in the cell.  In this 
regard, a comprehensive examination of the subcellular localizations of key 
signaling components may offer some insights. 
The sensitivity to death receptor apoptosis was not common to all 
ΔRING cell types, however: hepatocellular apoptosis occurred normally in 
vivo following intravenous administration of agonistic Fas antibody, or 
TNF-α together with the liver-selective transcriptional inhibitor GalN.  A 
key difference between death receptor apoptosis in MEFs and hepatocytes is 
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the obligate requirement for mitochondrial factors in hepatocyte apoptosis 
(Yin et al., 1999), and it is possible that one of these proteins modulates the 
effect of the ΔRING mutation.  This may also account for the otherwise 
normal cell death that occurs in embryonic cells killed by stimuli that act 
through the mitochondrial pathway of apoptosis. 
7.4 Implications for XIAP in tumor suppression and disease 
 
Although ΔRING mice appeared as healthy as WT littermates, we 
found an anti-apoptotic role for RING function after crossing mutant mice 
onto the Eµ-Myc transgenic background.  The importance of apoptosis in 
modulating cancer progression in Eµ-Myc mice is evident from animals 
carrying mutations in cell death genes (Schmitt et al., 2002; Strasser et al., 
1990).  We found small but reproducible increases in apoptosis in the 
population of proliferating, pre-malignant ΔRING B-cells in the bone 
marrow and in culture, and a general decrease in their relative abundance.  
This genetic evidence supports the long-standing notion that XIAP 
antagonism can lead to the death of cancer cells (Hunter et al., 2007).   
 In principal, it is possible to mimic the effects of the XIAP ΔRING 
mutation by using a small-molecule inhibitor of the RING (Sun, 2003).  Our 
results suggest that such an inhibitor may have therapeutic benefits in 
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lymphoma and leukemia, and possibly other malignancies.  A screen for 
XIAP RING inhibitors could use methods developed for identifying small-
molecule antagonists of the RING domain of Hdm2, the ubiquitin-ligase that 
suppresses p53 expression in human cells (Davydov et al., 2004; Murray et 
al., 2007).  Hdm2 RING antagonists repress autoubiquitination in vitro, 
increase the abundance of p53 in cells, and can induce apoptosis (Yang et 
al., 2005).  The inhibitors identified to date are neither very specific nor 
potent; however, the field is in its infancy, and optimized techniques will 
undoubtedly yield better inhibitors.  Another concern about using an XIAP 
RING inhibitor is raised by the observation that heritable mutations in XIAP 
underlie a human X-linked lymphoproliferative syndrome, characterized by 
increased TRAIL and Fas death receptor apoptosis and depletion of natural 
killer T-lymphocytes (Rigaud et al., 2006).  XIAP RING inhibitors may 
have a therapeutic window similar to bortezomib, a proteasome inhibitor 
currently in use as a treatment for multiple myeloma; multiple myeloma 
cells can be killed by apoptosis even by a modest decrease in proteasome 
activity (Chauhan et al., 2008).  
XIAP deficiency does not significantly alter tumor development in a 
mouse model of prostate cancer (Hwang et al., 2008).  This finding suggests 
that XIAP may not play a key role in the development of all tumors.  
 170 
However, emerging data implicate IAPs in regulating hematopoietic 
malignancies, melanoma and hepatocellular carcinoma, among other 
cancers.  The results presented here complement recent findings that genetic 
deletion of the Sept4 locus, which encodes the IAP antagonist ARTS, 
dramatically accelerates lymphomagenesis in the Eµ-Myc model (M. Garcia-
Fernandez, unpublished data).  The findings using mouse knockouts are 
entirely consistent with the hypothesis that XIAP has an anti-apoptotic role 
in lymphoid malignancy that can be inhibited by antagonists like ARTS.  It 
is very likely that more roles for IAPs will be uncovered in different 
malignancies.  For example, melanocytes upregulate ML-IAP during 
melanoma development and small-molecule IAP antagonists have entered 
clinical trials for treatment of this disease.   
Complementary roles for IAPs and IAP antagonists are observed in 
liver cancer as well.  cIAP1 gain-of-function has a causative role in 
hepatocellular carcinoma (Zender et al., 2006), while loss of the ARTS IAP 
antagonist dramatically predisposes mice to chemically induced 
carcinogenesis in the liver (C. Pham, unpublished data).  It is unclear if 
XIAP is the principal ARTS target in the liver, but it will be worthwhile 
investigating the roles of XIAP loss-of-function alleles, such as ΔRING, in 
mouse models of liver cancer.   
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The dramatic sensitivity to TNF-α and TRAIL apoptosis seen in 
ΔRING embryonic fibroblasts may also apply to other tissues and function in 
the response to inflammation or infection.  Although ΔRING hepatocytes 
activated caspase-3 with normal kinetics in response to TNF-α 
administration, other mouse models of infection or endotoxic shock may 
reveal sensitivity to apoptotic cytokine responses.  TNF-α has a causative 
role in inflammatory diseases like rheumatoid arthritis, where the 
inflammatory cytokines originate from TNF-α-stimulated synovial 
fibroblasts (Fox, 2000).  Perhaps the local inhibition of XIAP function in 
synovial joints by IAP antagonists could terminate the TNF-α signal by 
inducing apoptosis in fibroblasts, and subvert the long-term inflammatory 
effects.  It will also be worthwhile investigating apoptosis in diverse post-
mitotic cell types, since XIAP-deficiency or the ΔRING mutation predispose 
sympathetic neurons to apoptosis under culture conditions.  Collectively, our 
data demonstrate that XIAP, and RING function in particular, plays a far 
greater role in regulating apoptosis in vivo than was previously recognized. 
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8 APPENDICES 
8.1 Antibodies used for immunoblotting 
 
Antibody Manufacturer / order # Dilution 
Actin Sigma AC-15 1:20000 
Bcl-XL Cell Signaling 2764 1:1000 
Caspase-3 (p17) Cell Signaling 9661 1:1000 
Caspase-3 (p32/17) Cell Signaling 8G10 1:1000 
Caspase-3 (p32/p12) Gift from Joe Rodriguez 1:3000 
Caspase-7 Gift from Joe Rodriguez 1:1000 
Caspase-8 Cell Signaling 4927 1:1000 
Caspase-8 (cleaved) Cell Signaling 18C8 1:1000 
Caspase-9 Cell Signaling 9504 1:1000 
c-FLIP Cell Signaling 3210 1:1000 
cIAP1 R&D AF818 1:2000 
FADD Santa Cruz M-19 1:500 
NIK Santa Cruz H-248 1:500 
PARP BD clone C-2-10 1:2000 
Phospho-JNK Cell Signaling 9251 1:1000 
RIP1 Cell Signaling 4926 1:1000 
Smac/DIABLO BD monoclonal #56 1:1000 
Survivin R&D AF886 1:2000 
TAK1 Cell Signaling 4505 1:1000 
TNF-R1 Santa Cruz H-5 1:500 
Total JNK Santa Cruz sc-571 1:2000 
TRAF2 Cell Signaling 4712 1:1000 
Ubiquitin Sigma U5379 1:500 
XIAP BD monoclonal #28 1:1000 
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8.2 The curious case of the XIAP H466A/ΔRING mouse 
 
The XIAP ΔRING mouse was our second attempt to make a RING-
mutant allele.  Our initial approach was to knock-in a single amino acid 
substitution (H466A) in the RING, thereby removing a residue essential for 
RING function.  We also included the option to remove the domain 
altogether by flanking the sixth exon (encoding the RING) with loxP sites 
for excision by the Cre recombinase.  We positioned loxP sites in the final 
intron and 3’ UTR, so that Cre would excise the final exon and the splicing 
machinery would retain the final intron in the spliced mRNA (Figure A).  
Excising exon 6 would generate a truncated protein because of a fortuitous 
in-frame stop codon in the former final intron.  All steps of gene targeting 
were carried out successfully and chimeric mice transmitted the mutant 
allele through the germline.  We did some preliminary experiments with ES 
cells similar to those described above.  We were surprised to find that the 
XIAP H466A protein was virtually undetectable in ES cells after transient 
FLPe expression to delete the Neo box (Figure B).  We also deleted the final 
exon by expressing Cre recombinase using a self-excising, “hit and run” Cre 
recombinase retrovirus.  Deleting the final exon did in fact generate a 
truncated protein, but this too was expressed at nearly undetectable levels.  
Moreover, low XIAP H466A expression was seen in other cells (Figure C).  
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We obtained identical results after lysing cells in 8 M urea before 
immunoblotting.  Furthermore, XIAP H466A expression was insensitive to 
proteasome or lysosome inhibitors.  We found that the mRNA was 
expressed normally in MEFs after doing a Northern blot (Figure D).  We 
concluded that the loxP site in the 3’ UTR was inhibiting translation of the 
XIAP H466A message, perhaps by interrupting an element necessary for 
translation or by creating a micro-RNA binding site by accident.  
Furthermore, the XIAP H466A knockdown phenocopies a complete XIAP-
null in TNF-α-dependent apoptosis (Figure E). 
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Appendix Figure (A) Gene targeting strategy. Immunoblot of XIAP 
expression in H466A and ΔRING ES cells (B) and thymocytes/splenocytes 
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